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ABSTRACT 
The ideal vaccine can generate a strong immune reaction without adverse effects on the body. 
Thus, many vaccines are now created using recombinant technology to accomplish this goal. Purification 
of recombinant proteins produced in Gram negative bacteria (GNB) presents several challenges, includ-
ing reducing the concentration of contaminating host cell molecules to nontoxic levels. The most preva-
lent host cell molecule is lipopolysaccharide (LPS), which is a major constituent of the outer membrane 
of GNB. Residual LPS in final product presents a major problem for proteins intended for pharmaceutical 
application, as it is toxic to mammalian cells. An orthogonal approach is an FDA requirement for prepa-
ration of proteins intended for use as pharmaceuticals. The ideal approach not only reduces contami-
nants to acceptable measures, but also results in a high yield of properly folded protein, while maintain-
ing an expeditious time table and keeping costs low. Though a truly universal scheme for processing pro-
teins from GNB is not possible, a comprehensive study of scalable and certifiable methods currently 
used for protein purification will be performed on multiple constructs in order to outline general princi-
ples for the system in a helpful blueprint, evaluating the effectiveness of different methods of retrieval 
of protein from inclusion bodies in particular. This approach is based upon the hypothesis that produc-
tion of fusion proteins in the insoluble fraction results in a greater yield of pure protein with fewer pro-
cessing steps.  
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1. INTRODUCTION  
Industry is increasingly leaning towards the use of bacteria to produce various pharmaceutical 
products, particularly proteins. This is primarily because cultivation of bacteria saves both money and 
time in comparison to eukaryotic cell culture systems, and in addition a large amount of desired protein 
may be produced by bacterial systems. Industry leaders and researchers most commonly uses Esche-
richia coli as an organism-expression system, owing to the extensive knowledge base surrounding this 
organism (1). Because of the widespread use of E. coli, culturing techniques have been developed which 
enable the achievement of very high cell densities. Generally, the goal of bacterial protein production is 
to generate a high concentration of cells that then express the preferred protein efficiently and then en-
suring it is of high quality. It is very difficult to realize all these goals within the same procedure, so there 
is a constant effort to increase the pace and simplicity of production while maintaining high quality 
standards. 
A major concern of this system is the production of endotoxin by E. coli. As a Gram-negative 
bacterium (GNB), E. coli contains lipopolysaccharide (LPS) as a vital component of its outer cell mem-
brane, comprising 75% of the outer surface of E. coli (2). LPS is generally considered to be the major type 
of endotoxin, so named because of its close associated with the cell, thus differentiating it from secreted 
exotoxins. Once released from the surface of E. coli, which occurs both during rapid growth and lysis, 
LPS acts as a pathogen-associated molecular pattern (PAMP) and is a strong aggravator of the innate im-
mune response. The LPS associates with a circulating glycoprotein known as LPS-binding protein (LBP); 
when this complex interacts with CD-14, it is recognized by TLR4 (Figure 1.1). TLR4 response triggers the 
expression of several pro-inflammatory cytokines, which will in turn lead to inflammation and toxic 
shock. Because of the risk of endotoxemia in mammals, it is generally considered unacceptable for phar-
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maceuticals to contain >5EU/kg body weight (1EU is approximately 100pg of endotoxin) (3). The pres-
ence of endotoxins in the bloodstream can lead to toxemia, with symptoms including high fever, shock, 
bleeding disorders, organ failure, and death (4). 
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Figure 1.1 Interactions between LPS, LBP, and CD14 (5) 
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Removal of endotoxins is paramount to the safety of the bacterially-produced pharmaceuticals. 
This can be a difficult task as endotoxins are highly stable and often associate with the recombinant pro-
teins (6). The general structure of an LPS molecule consists of an O-antigen repeating chain and core oli-
gosaccharide (often referred to as the heteropolysaccharide region) covalently bound to Lipid A, a phos-
phoglycolipid. Lipid A is considered to be the toxic center of LPS, as bacteria deficient in Lipid A do not 
elucidate toxic shock in vivo (7). There is a significant amount of structural variation in the components 
of LPS among different bacterial species, especially in Lipid A. The general structure of Lipid A includes a 
phosphorylated disaccharide made of hexosamine residues, with fatty acid chains connected to the di-
mer. Different species possess distinctions in the structure of Lipid A, including the type of hexosamines, 
the degree of phosphorylation, and the number, location, and length of fatty acid chains. For E. coli it is 
well established that six asymmetrically organized fatty acid chains, containing fourteen carbons atoms 
each, are attached to a phosphorylated glucosamine dimer (Figure 1.2). The fatty acid chains of Lipid A 
generate a hydrophobic characteristic that allows LPS to form aggregates or strongly associate with 
other hydrophobic proteins, shielding the hydrophobic region. The core oligosaccharide, or heteropoly-
saccharide region, however, is hydrophilic. Together, these two regions give LPS an amphipathic charac-
teristic which makes them very difficult to remove from solution. Additionally, the phosphate groups of 
Lipid A provide a negative charge, which gives LPS an anionic characteristic as well (6). This feature sug-
gests that positively-charged proteins may be preferentially associated with endotoxin.  
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Figure 1.2 Diagram of cell envelope of Gram negative bacteria, inset Lipid A region of LPS (8) 
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Several methods have been developed to address the issue of sufficiently reducing endotoxins 
from microbially- derived protein solutions without tremendous sacrifice in yield or activity of the re-
combinant protein. As previously mentioned, LPS behaves as an amphipathic chemical because it con-
tains hydrophobic, hydrophilic, and anionic regions. These unique chemical characteristics of LPS make it 
exceptionally stable; using extremes in heat and pH would likely destroy target protein before endotoxin 
concentration is satisfactorily reduced (9). More commonly, chemicals or affinity sorbents that exploit 
one of the areas with a distinctive chemical trait (i.e. the hydrophobic region) are utilized to segregate 
the endotoxin from the target protein and then the two may be safely separated. Detergents or chelat-
ing agents such as Triton-X or EDTA are commonly used to dissociate endotoxin from the desired pro-
tein, but remaining chemicals can alter cell membrane fluidity characteristics and therefore be poten-
tially harmful to living cells (10). Additionally, residual detergents could be detrimental to the bioactivity 
of the target protein. Therefore, it is imperative that measures be taken to ensure there is no residual 
detergent or chelating agent in the preparation. Affinity chromatography with Polymyxin B has been 
shown to significantly reduce endotoxin (11), but if the target protein is strongly associated with endo-
toxin there is a risk of losing a significant amount of protein in this process (12). Size exclusion and filtra-
tion techniques for endotoxin removal are less effective, as there needs to be a significant difference in 
size between target protein and endotoxin. Combining a variety of approaches is widely accepted to be 
the most effective way of removing endotoxin efficiently without sacrificing the yield of the target pro-
tein (13). 
Given all that is known about the structure and behavior of endotoxin, and considering the lack 
of any purification scheme that is considered universally effective at removing endotoxin from recombi-
nant protein produced in GNB, designing recombinant proteins in silico may be a useful tool for future 
research efforts. Computational modeling has the potential to streamline the process of discovering an 
appropriate purification method, as researchers could design a recombinant protein that is unlikely to 
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associate strongly with endotoxin. Thus, screening potential constructs in silico has the potential to 
vastly streamline the purification scheme while assuring highest level of activity of putative fusion pro-
teins (unpublished work, Pierce lab). 
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1.1 Purpose of the Study 
 The intention of this project is to use an orthogonal multistep approach to deduce methods by 
which contaminating endotoxin can be effectively removed from microbially-produced recombinant fu-
sion proteins, and which purification conditions maintain the highest level of bioactivity. This is based on 
the development of a relatively new platform to generate fusion proteins produced in Gram negative 
bacteria for use as vaccines.  
 Transformed E. coli is grown in a large bioreactor and plasmid expression is induced once the 
bacteria have reached a desired concentration. The fed-batch fermentation procedure has been opti-
mized to increase cell yield and maximize the expression of the plasmid containing the recombinant pro-
tein. After fermentation, the cells are harvested and dewatered using a continuous flow 2-phase separa-
tion device, generating a thick cell paste. Once the cell paste is collected, the cells are disrupted and 
clarified via a multi-step process. Each step of this process is specifically geared to reduce cellular con-
taminants to within an acceptable range, yielding the largest possible amount of highly effective, puri-
fied protein (Figure 1.3).  
 Protein purification from microbial systems traditionally focuses on purification from the soluble 
fraction, due to the perceived difficulty of retrieval of native protein from within insoluble fraction. 
Overexpression of recombinant proteins in bacterial systems, especially E. coli, tends to result in the for-
mation of aggregates of misfolded or partially folded intermediates (14). These aggregates, or inclusion 
bodies (IB), have many characteristics that make them readily segregate from other cellular components 
and fermentation media, a property that may be exploited in order to reduce the number of purification 
steps required to retrieve target protein. It is generally considered preferable to utilize mainly physical 
means for purification: this approach reduces the number of downstream steps required to remove 
chemical additives introduced in earlier steps (11). Additionally, there tends to be a high amount of pro-
tein within IBs and this protein is less likely than cytosolic protein to associate closely with other cellular 
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debris (15). Thus, there are advantages to exploring and optimizing purification schemes which focus 
specifically on the recovery of active protein produced within inclusion bodies. 
  One of the aims of this study is to evaluate each step of the protein purification procedure, as-
sessing the effectiveness of different techniques on endotoxin reduction and activity of target protein. 
This assessment will be weighed against the time and resources required for each step or phase of the 
purification procedure, with the intent of establishing an optimized and efficient purification scheme.  
 
 
Figure 1.3 Protein purification scheme  
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 A future concern for protein purification from GNB is taking measures to reduce the iterative 
nature of the process. Initial purification steps are consistent regardless of target protein conformation, 
but little is known about how to predict which purification scheme is ideal for different proteins. In fact, 
there is no consensus about which properties of a protein make it more likely to be produced within the 
insoluble or the soluble fraction (16). Recombinant proteins overexpressed in E. coli tend to form cyto-
plasmic inclusions, especially when an inducer is used. It is widely accepted that this phenomenon is due 
to the amount of protein expressed overwhelming the chaperone system, and the likelihood of protein 
to form intermediates under the reducing conditions of the cytoplasm (17). Putative fusion proteins 
could be evaluated for structural and chemical similarity to other recombinant proteins using in silico 
modeling, and purification procedures adopted which best fit the characteristics of the fusion protein. 
While it may not be possible to completely prepare a purification scheme a priori, this approach could 
certainly reduce the time and cost associated with determining an ideal scheme for protein preparation. 
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1.2 Description of Constructs 
The fusion proteins generated for this project include flagellin protein (from Salmonella typhi-
murium), the major component of bacterial flagellar filament, because it acts as an agonist for toll-like 
receptor 5 (TLR5). TLRs recognize structurally conserved ligands/antigens present on microorganisms 
and play a fundamental role in the induction of the adaptive immune response (18, 19). There are 11 
known TLRs, each with different specificity, and TLR5 is specific for flagellin. Unlike the other TLRs, TLR5 
is the only TLR that recognizes a protein, making it an ideal innate immune system activator. Linkage of 
TLR5 ligands to vaccine antigens has been shown to increase immunopotency of the linked antigen (20, 
21). Flagellin alone has been shown to act as an adjuvant to vaccines (22). Structurally, flagellin contains 
5 domains, 4 of which directly interact with TLR5 (D0-D3). Of these, D0 and D1 are highly conserved and 
correspond to the C and N termini and are required for activation of the innate immune response via 
TLR5. The central regions, D2 and D3, are considered hypervariable and not required for activation of 
TLR5 (23). However, a portion of the D3 region is required for correct folding of flagellin, thus care must 
be taken if excising portions of the hypervariable region.  
A construct was created in which full-length flagellin (FliC) from S. typhimurium was cloned into 
a plasmid vector and expressed in E. coli and grown in a bioreactor. The fermentation product (known as 
FA-4), was then purified following a purification scheme which evaluated the effectiveness of multiple 
purification conditions. This construct was generated for the purpose of evaluating the purification pro-
cesses necessary for the full-length flagellin protein, under the presumption that fusion proteins based 
upon TLR5 stimulation by flagellin could be similarly purified. As previously mentioned, flagellin is suffi-
cient to initiate a pro-inflammatory innate immune response. Use of flagellin as an adjuvant has been 
shown to increase effectiveness of vaccines, thus the development reliable method for rapid producing 
large amounts of highly pure, biologically active flagellin from a microbial system would be highly bene-
ficial. 
12 
 
 
 
Figure 1.4 Domains of Full-length flagellin (23) 
 
 
 
 
 
Figure 1.5 Structure of flagellin monomer and filament (24)  
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To construct the two fusion proteins used, fliC (S. typhimurium flagellin protein) was fused to 
immunologically significant regions of two different viruses in order to function as recombinant vac-
cines. Common production of vaccines is accomplished by disabling or inactivating the whole pathogen 
which may result in occasional adverse reactions. Subunit or recombinant vaccines can be advantageous 
because only the antigenic portion of the pathogen is introduced into the body, thus the safety of the 
vaccine is ensured. A challenge commonly associated with subunit and recombinant vaccines is the ten-
dency of the resulting immune response to be somewhat weak. By fusing antigenic portions of viruses 
with flagellin, the effectiveness and safety of vaccines can be ensured. Once the recombinant constructs 
were created, they were then cloned into plasmid vectors and expressed in E. coli, grown in a bioreac-
tor, and purified according to the schematic above (Figure 1.6). This imparts another advantage over tra-
ditional vaccine preparation: growing recombinant vaccines in a bioreactor may greatly increase yield 
(the average yield for prokaryotic systems is 3-4 x105 doses/L). The two viruses chosen for this analysis 
were influenza virus and Marburg virus.  
The first recombinant protein (designated STF2:HA1-2, Solomon Island (SI)) linked full-length fla-
gellin (FliC) to a globular head subunit of Influenza A hemagglutinin (Figure 1.6). The morbidity of sea-
sonal influenza virus is very high, causing well over 200,000 hospitalizations annually; additionally, it is 
indicated in an average of 30,000 deaths per year in the United States alone (25). Therefore, the availa-
bility of effective vaccines is of utmost importance to public health. The current vaccine is, at last report, 
indicated to be 47% effective against influenza A virus (26). Additionally, all of the current seasonal flu 
vaccine formulations are derived from virus grown in fertilized bird embryos; a new exception is the re-
cently-approved Flucevlax, which is derived from virus grown in animal cell culture (27). Growth of vi-
ruses is notoriously difficult, as they are obligate intracellular parasites. Use of fertilized eggs as a means 
for viral growth is effective but is unfortunately time consuming. A significant problem with manufacture 
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of the seasonal influenza vaccine is that production of the world’s supply is a timely process, and dimin-
ishes the time available to effectively manufacture a vaccine against a pandemic strain (e.g. H5N1 or 
H7N9) should the need arise (28). An ideal vaccine would have a higher efficacy against the circulating 
strain of seasonal influenza A, could be manufactured in a timely manner, and would be allergen (oval-
bumin) free. Early results indicate that purified STF2.HA1-2 (SI) also elicits a strong immune response in 
mice (20).  
The purification procedure for STF2.HA1-2 (SI) was evaluated previously for protein produced 
within the soluble fraction under a specific set of denaturing conditions. This project expanded on the 
methodology used to extract the fusion protein in order to provide feedback following evaluation of dif-
ferent approaches. 
 
 
 
Figure 1.6 Structure of the recombinant protein STF2:HA1-2 (20) 
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The final construct tested was a fusion protein in which the C-terminal region of flagellin was 
linked to a short epitope region of Marburg virus (GP132), and given the designation GP132:FliC (Figure 
1.7). Marburg virus (MARV)is an agent of hemorrhagic fever. Prevalence of MARV is low, even in the 
populations in which it is considered endemic. However, MARV is considered an extremely dangerous 
human pathogen. In recent outbreaks, the mortality rates have reached 90% (29). Within as short as 5 
days, infected individuals exhibit high fever, diarrhea, severe headaches, and malaise, and the possibility 
of hemorrhage and progressive organ damage. This symptom set can be very debilitating and due to the 
excessive fluid loss experienced by infected individuals, MARV is highly transmissible person-to-person. 
Additionally, there is no treatment beyond supportive care, which may be precluded in an outbreak situ-
ation: during an outbreak it might be difficult to secure sufficient necessary medical facilities, supplies, 
and staff to treat affected individuals. Thus, MARV is considered a potential bioterrorism agent (30).  
Because this fusion protein was completely novel, the preferred method for extraction from the 
cell and subsequent purification was not established. Again, multiple purification methods were imple-
mented and evaluated, building a purification scheme that met both the criteria of low contamination 
and high activity. 
 
 
Figure 1.7  Structure of fusion protein designated FliC:GP132 
 
 
FliC GP132 
N-terminal TLR5 
Recognition site 
C-terminal TLR5 
Recognition site 
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1.3 Expected Results  
Variation in the purification process is conditional upon whether the desired protein is produced in the 
soluble or insoluble fraction, or in combinations thereof. Production in the soluble fraction traditionally 
has been considered advantageous because the expressed protein is readily accessible for purification. 
However, in the soluble fraction, recombinant protein is more exposed to contaminating host protein, 
including destructive proteases, and must thusly be dissociated from contaminants. Additionally, pro-
teins present in the soluble fraction preferentially associate with endotoxin. This implies that more puri-
fication steps be involved, which not only typically sacrifice the integrity of the native structure of the 
protein, but also increase the time, cost, and potential for user error due to the increased number of 
steps during the purification procedure (31).  
 If the recombinant protein is produced in inclusion bodies within the insoluble fraction, the ap-
parent hurdle is to resolubilize the protein. The standard purification approach has been to focus on the 
soluble fraction because of the necessity to renature proteins recovered by the resolubilization step, 
which has historically been accomplished using strong denaturing conditions. This renaturation step has 
been characterized to be both the most expensive and time-consuming (32). However, the environment 
within inclusion bodies normally contains only the target protein (33). The higher level of protein expres-
sion in inclusion bodies combined with the natural shielding from degradation by proteases make purifi-
cation from inclusion bodies desirable, if not preferable to, the standard approach. Therefore, a practical 
approach that accomplishes renaturation efficiently should have a more efficient purification procedure, 
thus making production of target protein within the insoluble fraction advantageous (34). The proposed 
approach explores a range of the concentrations of the denaturants during the resolubilization step. 
Studies have shown that using a low concentration of denaturing agent at this stage of purification may 
result in fewer aggregates forming. It has been indicated that the use of urea as a denaturant may en-
hance the formation of protein aggregates in IBs due to hydrogen bonding interactions that affect the 
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formation of protein native structure (35). It is therefore hypothesized that using a lower concentration 
of denaturant may reduce misfolded protein aggregates and that the use of Guanidine-HCl as a denatur-
ant, rather than urea, may yield high quality fusion protein from IBs. The hypothesized approach uses 
less stringent denaturing chemicals in order to reduce the likelihood of misfolded fusion protein or in 
formation of aggregates upon resolubilization from inclusion bodies (Figure 1.8). 
 
 
 
Figure 1.8 Comparison of insoluble and soluble fractions of fermentation product 
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Aspects of the purification process beyond whether the protein is produced in the soluble or in-
soluble fraction and the conditions involved in resolubilization of target protein will be considered. 
While it is a well-accepted generalization that protein overproduced in E. coli forms inclusions, purifica-
tion of protein that may have been secreted from cells during fermentation will also be attempted. Ad-
ditionally, conditions for the final refold step are evaluated, including analyzing the effect that varying 
redox pair systems and the amount of time refolding allowed may have on the integrity of purified pro-
tein. During this stage, the denaturing conditions are reversed either by dilution or dialysis in order to 
completely renature resolubilized protein while minimizing the formation of misfolded protein. Redox 
pairs (oxido-shuffling systems) are typically included in refolding buffers to achieve maximum yield and 
peak renaturation of target protein, as protein is more likely to fold into native conformation under oxi-
dizing conditions (36). 
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2. EXPERIMENT 
2.1 Preparation of Constructs 
Purification procedural experiments were conducted on proteins constructed using recombinant 
DNA technology with the intention of using them as vaccines. Three such constructs were studied: a full-
length flagellin and two fusion proteins built by linking flagellin with a truncated monomer of an anti-
genic portion of a virus. The full-length flagellin construct was prepared at Georgia State. The purpose of 
this construct was to evaluate systems for the purification of flagellin, since this protein itself has immu-
nogenic properties, as well as to act as a point of comparison for the fusion proteins. To generate this 
construct, the full-length sequence of the flagellin protein from S. typhimurium (FliC) was ligated into 
the pETBlue™ plasmid (Merck, Whitehouse Station, NJ) using complementary restriction endonuclease 
cut sites. It was then transformed into the expression host: competent DE3 E. coli. A successful clone 
demonstrated induction of the plasmid and was designated FA4. 
The first fusion protein, STF2:HA1-2 (SI), was acquired from and prepared by a group within pri-
vate industry using similar protocols. Briefly, the gene for the globular head domain of hemagglutinin A 
was generated synthetically and fused to the C-terminus end of a full-length flagellin monomer (FljB) 
from S. typhimurium. The resulting fusion protein was inserted into the pET24 plasmid to yield the con-
struct (20). Next, the plasmid was transformed into host in preparation for growth in a bioreactor. 
To generate the FliC:GP132 fusion protein, GP132, oligonucleotide containing restriction enzyme 
cut sites was generated synthetically (Integrated DNA Technology, Coralville, Iowa). GP132 is a 9-mer 
peptide (15-mer amino acid sequence: GILLLLSIAVLIALS) derived from the glycoprotein region of Mar-
burgvirus and was found to act as an effective vaccine in mice: stimulating cytotoxic lymphocytes, result-
ing in the production of interferon γ, and offering complete protection upon challenge with Mar-
burgvirus (37). The flagellin sequence was inserted into the pETBlue plasmid and the GP132 gene was 
ligated to the C-terminal end of the FliC flagellin gene. The plasmid containing the fusion protein was 
20 
 
then transformed into competent DE3 E. coli as above. A successful clone (one that expressed the fusion 
protein upon induction) was entitled 5088. 
2.2 Fermentation and Initial Purification 
The two constructs developed at GSU (FA4 and 5088) were expressed after induction with iso-
propyl β-D-1-thiogalactopyranoside (IPTG) during a batch-fed 20L fermentation. IPTG induces expression 
of genes regulated by the lac operon by disabling the lac repressor (38). This results in high-density ex-
pression of recombinant proteins in E. coli. During fermentation, the temperature was maintained at 
30⁰C, dissolved oxygen was maintained at 35%, and glucose was provided in a constant feed once the 
initial glucose concentration was depleted. The STF2:HA1-2 (SI) fusion protein was expressed by a similar 
protocol. 
Overexpression of fusion proteins in E. coli does not always yield easily purified soluble pro-
teins.  Often, recombinant proteins are produced in dense insoluble aggregates within the cytoplasmic 
or periplasmic space known as inclusion bodies (IBs).  Until recently it was believed that inclusion bodies 
contained solely misfolded non-functioning proteins.  As of late, the advantages of overproducing target 
protein within a defined environment inside E. coli have been noted (33), and several procedures have 
been modified to exploit this feature (39, 40). 
After the completion of fermentation, excess water was removed from the harvest using the 
Powerfuge Pilot (Carr, Clearwater, FL).  This platform separates solid from liquid using simultaneous cen-
trifugation and vacuuming, and processes at a rate of up to 60L/hour.  Solid product obtained from the 
Powerfuge was designated “cell paste” and was immediately processed further or was stored at -80℃.  
If cell paste was stored, prior to processing it was thawed overnight at 4℃.  Once thawed, the cell paste 
was evaluated for solidity.  Depending on the firmness of the cell paste, it was diluted to either 7.5% or 
15% solids using a 4% sucrose lysis buffer (P1) and stirred to mix completely.  The diluted cell paste was 
then homogenized without pressure using an APV homogenizer (APV-1000, Delavan, WI) to generate a 
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fully resuspended cell paste.  Resuspended cell paste was homogenized under pressure (690bars, equiv-
alent to 10,000psi) in triplicate to completely lyse cells. Between homogenization passes, the resus-
pended cell paste was passed through a cooling coil to lower the temperature to no more than 5℃. This 
step was included as a control measure to reduce the risk of early denaturation of the target protein by 
heat. The resulting lysate was partially clarified by an initial centrifugation step, yielding both an insolu-
ble fraction (pellet) and a soluble fraction (supernatant), both of which were analyzed (via SDS PAGE gel 
electrophoresis) for the presence of the target protein. Both fractions were processed further to deter-
mine which method emerged as more advantageous. 
Cellular material was removed from the insoluble fraction by washing twice with ethylenedia-
minetetraacetic acid (EDTA) and Triton X-100, and then washing with a 0.3M urea solution. To extract 
the protein from inclusion bodies, the washed pellet was resuspended in varying concentrations of de-
naturant: either urea or guanidine-HCl. The concentrations of denaturant used ranged from 1M to 8M 
(Table 2.1). Following introduction of the denaturant, the resuspended pellet was centrifuged, yielding a 
refined lysate (RL).  Because the RL was obtained from within inclusion bodies, it required fewer purifi-
cation steps than RL from the soluble fraction.  
 
Table 2.1 Denaturant Concentrations 
Construct Urea concentrations tested Guanidine-HCl concentrations tested 
FA-4 1M, 2M, 4M, 6M, 8M 1M, 2M, 4M, 6M 
STF2:HA1-2 (SI) 1M, 2M, 4M, 6M, 8M 1M, 4M, 6M 
5088  1M, 6M 
 
2.3 Additional Purification of the Soluble Fraction 
Proteins present in the soluble fraction (the supernatant after initial centrifugation) were precip-
itated with polyethylene glycol (PEG) 3350 and centrifuged to separate precipitated proteins.  As with 
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the insoluble fraction, the PEG pellet was resuspended in varying concentrations (see Table 2.1) of either 
Guanidine-HCl or urea to resolubilize desired protein.  Insoluble solids were removed by a final centrifu-
gation step to yield RL.  This RL was then further purified to reduce contamination by endotoxins tightly 
associated with the desired protein.  
2.3.1 Tangential Flow Filtration (TFF) 
Refined Lysate obtained from the soluble fraction underwent a minimum of five passes through 
a Centramate (Pall, Port Washington, NY) tangential flow filtration membrane (1ft2, 30kD molecular 
weight cut-off) to exchange denaturant-containing buffer for 50mM Tris buffer.  Once the conductivity 
of the waste measured within a 10% range of the conductivity of the 50mM Tris buffer, the buffer ex-
change was satisfactorily completed.  In addition to reducing the endotoxin, this filtration method facili-
tated the reduction of the nucleic acid concentration as reported by the Nanodrop 2000 (Thermo 
Fischer Scientific, Wilmington, DE), a micro-volume spectrophotometer.  High concentrations of nucleic 
acids are known to interfere with anion exchange chromatography. 
2.3.2 Two-Phase Separation 
The detergent Triton X-114 was added to the TFF product, along with PEG. This technique uti-
lized the hydrophobic nature of endotoxins, which associate preferentially with the surfactant to form a 
micelle. Centrifugation yielded a clarified aqueous phase and a disposable detergent phase, which con-
tained the micelles. Thus endotoxins were discarded with the detergent phase (41). The aqueous phase 
was filtered in preparation for anion exchange chromatography. 
2.4 Anion Exchange Chromatography (AEX) 
AEX was used to remove charged impurities, including remaining host cell protein, endotoxin, 
incorrectly folded proteins, and buffer components from product derived from both the soluble and in-
soluble fractions.  The recombinant protein was denatured in varying concentrations of either urea or 
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Guanidine-HCl, then refolded by diluting denatured protein into a nine-fold excess of refolding buffer 
(27, 42). Samples were allowed to refold for a period of two hours or overnight and quality of refolded 
protein was evaluated. The activity of protein refolded using two different oxido-shuffle systems (gluta-
thione and cysteine) was assessed. Refolded protein was then loaded onto a pre-packed ToyoScreen col-
umn with SuperQ-650 resin, a known strong anion exchanger (Tosoh Bioscience, Stuttgart, Ger-
many).  The column was run on the ÄKTAexplorer® automated liquid chromatography system (GE 
Healthcare Biosciences, Uppsala, Sweden), and eluted as a single peak at a low salt concentration. Endo-
toxin remained bound to the column until it was washed with solution with a significantly higher salt 
concentration, thus further removing it from the product.  This step also removed any remaining surfac-
tant and nucleic acid (43).  
2.5 Purification of Full-length Flagellin 
2.5.1 Purification of the Insoluble Fraction 
Cell paste generated via fermentation was thawed at room temperature and centrifuged to re-
move fluid. The pellet was resuspended in sucrose buffer using sonication. Resuspended cell paste was 
homogenized under pressure to lyse cells and then was centrifuged to separate the soluble proteins in 
suspension from the insoluble fraction contained within the pellet. The pellet was washed and resus-
pended in varying concentrations of urea or guanidine-HCl to generate clarified harvest. Clarified har-
vest was allowed to refold overnight in 9x refolding buffer. Refolded proteins were loaded onto a 
SuperQ column and eluted via AEX. 
2.5.2 Purification of the Soluble Fraction 
Following initial centrifugation, PEG 3350 was added to the supernatant (soluble fraction) to 
precipitate proteins. The soluble fraction was centrifuged again; this time the pellet was collected and 
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resuspended in varying concentrations of urea or guanidine-HCl. Tangential flow filtration was per-
formed to exchange the denaturing buffer for Tris buffer. Triton X 114 was added to associate with the 
insoluble region of endotoxin and form micelles. These impurities were removed by centrifugation, and 
the aqueous phase was collected and filtered. The filtered aqueous phase was then added to 9x refold-
ing buffer and allowed to refold overnight. The refolded protein was finally purified after anion ex-
change, which was accomplished using automated HPLC. 
2.6 Purification of STF2:HA1-2 (SI) 
2.6.1 Purification of Insoluble Fraction 
Frozen cell paste obtained from fermentation was thawed at room temperature and resus-
pended in sucrose buffer. After homogenization, the clarified harvest was centrifuged to separate the 
soluble and insoluble fractions. The insoluble fraction (the pellet) was resuspended in buffer prepared 
with varying concentrations of urea or guanidine-HCl (Table 2.1). The resulting clarified harvests were 
diluted to a concentration of 2mg/mL and refolded overnight in preparation for anion exchange chroma-
tography. Refolded protein was then loaded onto a SuperQ column and eluted either via a stepwise or 
gradient method. Eluate was collected and stored at 4℃. Process samples from each stage of purifica-
tion were analyzed for quality by SDS-PAGE, BCA protein assay, and ET assay. 
2.6.2 Purification of Soluble Fraction 
After initial centrifugation, the soluble fraction present in the solution was treated with PEG to 
precipitate proteins. Precipitated proteins were collected after additional centrifugation as the pellet. 
This pellet was resuspended with varying concentrations of urea or guanidine-HCl and centrifuged again 
to remove any insoluble solids, yielding refined lysate. Buffer exchange was achieved using tangential 
flow filtration and the TFF product was further clarified by two-phase separation followed by filtration. 
Refined lysate was diluted to 2mg/mL and allowed to refold overnight. Refolded protein was then 
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loaded onto a SuperQ column and eluted either via a stepwise or gradient method. Eluate was collected 
and stored at 4℃. Again, samples taken during each stage of the procedure were analyzed for quality by 
multiple validation measures. 
2.7 Purification of FliC:GP132 
2.7.1 Purification of Insoluble Fraction 
Cell paste from fermentation was allowed to thaw and then was resuspended in a sucrose 
buffer. Homogenization under pressure ensured that the cells were lysed sufficiently. An initial centrifu-
gation step separated the insoluble fraction from the soluble fraction. The insoluble pellet was rinsed 
and then resuspended in varying concentration of guanidine-HCl. Anion exchange was then performed 
to reduce impurities. Process samples were analyzed by several methods to assure quality and to deter-
mine optimal conditions for purification. 
2.7.2 Purification of Soluble Fraction 
PEG 3500 was added to the supernatant from the initial purification step in order to solidify any 
proteins present. This solution was centrifuged, and the pellet was collected and resuspended with 
buffer containing varying concentrations of guanidine-HCl in order to resolubilize target protein. An-
other centrifugation removed any insoluble impurities, resulting in refined lysate. The refined lysate 
was then passed through tangential flow filtration to exchange the denaturing buffer for a Tris buffer. 
Following buffer exchange, Triton X-114 was added in order to form close associations with the nonpo-
lar regions of LPS. Centrifugation forced these impurities into the detergent phase, which was dis-
carded. The aqueous phase was filtered and allowed to refold overnight using varying redox species in 
the refolding buffer: cysteine/cystine or glutathione redox systems. Finally, anion exchange was per-
formed to remove any remaining impurities. 
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2.7.3 Purification of Secreted Protein 
Process samples from fermentation indicated that target protein was present in the conditioned 
media (CM), rather than solely within cell paste (Figure 2.1). Thus, a platform to purify protein which 
may have been secreted during fermentation was also tested. Spent media from fermentation was col-
lected and initially clarified by centrifugation (8000rpm, 45min). Both the supernatant and pellet were 
collected and processed by secondary purification methods in order to determine the efficacy of purifi-
cation of secreted protein. 
 
Figure 2.1 Pre and Post-Induction Fermentation Samples (FliC:GP132) 
  
27 
 
2.8 Validation  
2.8.1 Western Blotting 
Western blotting was done in order to provide additional confirmation of the presence of fusion protein 
in samples from various stages of the purification process. The preparations that were carried through 
to AEX were analyzed by Western blotting, performed using primary antibody specific for FliC flagellin 
from Salmonella typhimurium. Protein was loaded onto a polyacrylamide gel and separated on the basis 
of size via gel electrophoresis. Blotting of the gel was accomplished by sandwiching the gel and a pre-cut 
cellulose membrane between soaked blotting pads. Protein was then electrophoretically transferred to 
the cellulose membrane using the Xcell II® Blot Module (Invitrogen, Grand Island, NY) at 360mA for 
1hour. The membrane was then blocked with 0.5% milk solution to reduce nonspecific binding of anti-
bodies. After blocking, the transfer membrane was washed in triplicate and incubated with the primary 
antibody: anti-FliC. Secondary antibody (rat anti-Mouse IgG horseradish peroxidase (HRP)) was applied 
in order to be detected by chemiluminescence. Finally, the image was created using Western Lightning-
Plus-ECL, Enhanced Chemiluminescence Substrate (Perkin Elmer, Walthan, MA) and the ImageQuant® 
LAS 4000 (GE Lifesciences, Piscataway, NJ). 
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Figure 2.2 Western Blot Procedure (from MilliporeSigma) 
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2.8.2 TLR5 Bioassay 
The TLR5 bioassay was performed in order to provide verification of the presence of active FliC 
in purified samples, thus indicating proper folding of the inserted protein. The preparations that were 
carried through to AEX were analyzed by a TLR5 ligand stimulation assay (adapted from InvivoGen, San 
Diego, CA). In this assay, HEK-Blue hTLR5® cells were co-transfected with an hTLR5 gene and secreted 
embryonic alkaline phosphatase (SEAP) gene under the control of NF-κB promoter. Stimulation of hTLR5 
by flagellin activated NF-κB, inducing production of SEAP. A detector, Quanti-Blue® was used to indi-
rectly detect the amount of alkaline phosphatase present due to the stimulation of hTLR5 via changes in 
optical density. Increases in optical density were considered directly proportional to increases in TLR5 
activity. Samples were compared with a flagellin standard (positive control) and ET-free water (negative 
control) in order to determine activity of purified protein. Additionally, HEK-Blue Null® cells were used in 
this assay to correct for endogenous TLR5 in HEK cells. 
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Figure 2.3 Process of TLR5 Bioassay for Validation of Innate Immune System Activation 
  
Plate preparation
• Add test samples, controls to bottom of wells
• Add 180μL of cell suspension (~25,000 cells) per well.
• Incubate the plate at 37°C in a CO2 incubator for 20-24 h.
Absorption reading
• Add 180μL of QUANTI-Blue™ per well of a flat-bottom 96-well plate.
• Add 20μL of induced HEK-Blue™-hTLR5 Cells supernatant OR induced HEK-Blue™-Null1 
Cells supernatant
• Incubate the plate in a 37°C incubator for 1-3 h.
• Determine SEAP levels using a spectrophotometer at 620-655 nm.
Calculate Corrected Activity
• ΔOD between TLR5 and null
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2.8.3 Endotoxin Assay 
All preparations that were carried through to AEX were tested to determine the amount of en-
dotoxin remaining after each step of the purification process. This is a necessity in order to maintain 
compliance with current Good Manufacturing Practices (cGMP). The current FDA standard for measure-
ment of endotoxin is the Limulus amebocyte lysate (LAL) kinetic chromogenic assay (Kinetic-QCL®, 
Lonza, Walkersville, MD). The basis of the assay is the response of horseshoe crabs to GNB. Presence of 
LPS leads to degranulation of amebocytes, releasing the protease zymogens and pre-clotting enzyme 
which are involved in a cascade resulting in coagulation. Factor C is a LPS-binding protein, that, once ac-
tivated by LPS, will in turn activate Factor B. Activated Factor B is then able to convert the pre-clotting 
enzyme into its active form, which leads to the formation of a gel clot. This pathway traps the bacteria in 
the clot, thus helping the horseshoe crab evade infection (14). The commercial LAL assays contain one of 
the proenzymes, which will split a chromogenic substance from a colorless substrate, causing a color 
change (Figure 1.3). This color change is measured continuously throughout the course of the reaction, 
and the reaction time is inversely related to the endotoxin concentration in the measured sample. Di-
luted samples were combined with the LAL reagent and substrate mixture and placed inside an incubat-
ing plate reader. Each assay was run along with an endotoxin standard, diluted serially, to generate a 
standard curve to determine the concentration of endotoxin in each sample.  
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Figure 2.4 LAL Kinetic Assay for Endotoxin Detection (44) 
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2.8.4 BCA Protein Quantification 
All samples were subjected to a BCA (bicinchoninic acid) chromogenic protein quantification 
(Pierce™ BCA Protein Assay, ThermoFischer Scientific, Waltham, MA) in which the optical density of 
each sample combined with the BCA reagent was measured at a wavelength of 562nm. The relation-
ship between optical density and protein concentration is directly proportional, thus this method pro-
vides an accurate measure of the amount of target protein produced. 
 
 
Figure 2.5 BCA Protein Quantification Assay 
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2.8.5 SDS-PAGE assay 
All samples were run using sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-
PAGE) to visualize the production and purification of the target protein. Samples were diluted and 
added to buffer prior to being loaded into the gel. Electrophoresis was allowed to continue for an hour 
and then the gel was stained with Coomassie blue. The gel was destained with water and then imaged 
on a light box. 
 
 
Figure 2.6 SDS PAGE Assay (Wangler, 2017) 
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3. RESULTS  
3.1 Results for FliC 
During initial purification of the full-length flagellin construct, both insoluble and soluble frac-
tions were processed using varying concentrations of Urea (1M-8M). Process samples were taken and 
protein quantified using a BCA protein assay. Additionally, these samples were run using SDS-PAGE to 
detect target protein (55kDa) (Figures 3.1, 3.2). Based on early sampling, the relationship between dena-
turant concentration and yield of target protein appears to be directly proportional. There was a re-
duced yield of protein in the insoluble fraction compared to soluble: insoluble refined lysate protein 
yield ranged from 542 – 1733μg/ml, while the range for soluble refined lysate ranged from 987μg/ml to 
9684μg/ml. However, protein produced in the soluble fraction required additional processing, so these 
results were anticipated. Following initial purification of the insoluble fraction, the refined lysate was 
refolded for at least 2 and up to 24 hours using varying redox systems in the refolding buffer and sam-
ples were filtered prior to anion exchange chromatography. 
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Figure 3.1 SDS PAGE 1 of Initial Purification of FliC from 20 Liter Fermentation Run.  
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Figure 3.2 SDS PAGE 2 of Initial Purification of FliC from 20 Liter Fermentation Run.  
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The initial processing of the full-length flagellin construct was repeated using varying concentra-
tions of Guanidine-HCl (Gdn-HCl) (1M-6M) as the denaturant (Figures 3.3, 3.4). Again, based on early 
sampling, there is a directly proportional relationship between denaturant concentration and protein 
yield. Notable exceptions to this trend were samples processed by the insoluble procedure using 1M 
Gdn-HCl: these samples had similar protein yield (1264μg/mL) as samples processed using a much 
higher concentration of denaturant. Because these samples had high protein concentration and used a 
lower concentration of Gdn-HCl, these samples were selected further processing along with samples 
processed using 6M Gdn-HCl. Following initial purification of the insoluble fraction, the refined lysate 
was refolded for at least 2 and up to 24 hours using varying redox systems in the refolding buffer. Sam-
ples were then filtered in preparation for column loading. The protein yield was again slightly higher in 
the soluble fraction, though the difference was not as great compared to the results when urea was 
used as the denaturant. This trend was expected, as the soluble fraction requires additional downstream 
steps before anion exchange chromatography. 
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Figure 3.3 SDS PAGE 3 of Initial Purification of FliC from 20 Liter Fermentation Run.  
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Figure 3.4 SDS PAGE 4 of Initial Purification of FliC from 20 Liter Fermentation Run 
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Refined lysates resulting from the soluble purification procedure required further clarification 
using TFF and 2-phase separation procedures. Only samples which were initially purified using 6M Urea 
had adequate protein remaining (892μg/ml) after secondary purification to be further processed (Figure 
3.5). These samples were filtered following the 2-phase centrifugation step in order to be processed by 
anion exchange chromatography.  
 
 
Figure 3.5 SDS PAGE of TFF and 2 Phase Separation of FliC from 20 Liter Fermentation Run.  
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Samples prepared by the insoluble procedure using either 1M or 6M Gdn-HCl, and samples pre-
pared by the soluble procedure using 6M Urea had adequate protein yield to be processed through to 
anion exchange chromatography. Western blotting revealed similar hybridization patterns for protein 
processed in both the insoluble and soluble fractions (Figure 3.6). The presence of the 55kDa band cor-
responding with FliC is clearly present in all samples prior to AEX; the band is not visible in the samples 
which follow AEX and this is likely due a low concentration of the sample being loaded onto the gel. Dur-
ing anion exchange elution, a large peak was seen that corresponded to purified FliC. This is depicted on 
the chromatogram (Figure 3.7: this sample was processed via the insoluble procedure using Gdn-HCl 
(1M) as the denaturant); protein concentration of this peak was quantified using a BCA protein assay 
(377µg/mL). Following anion exchange, endotoxin assays indicated that both procedures yielded a low 
concentration of endotoxin (Table 3.1). Results from the endotoxin assay show that refined lysate from 
insoluble and soluble clarification procedures had similar levels of contamination due to host cell lipo-
polysaccharide. The insoluble preparations that underwent AEX had much lower ET levels than soluble 
preparations, however the 6M Gdn-HCl preparation contained no detectable protein. The soluble prepa-
rations had detectable protein at all stages but had a significantly higher level of endotoxin after AEX 
than insoluble preparations (Figure 3.8). This finding indicates that protein within the soluble fraction 
may be more difficult to decontaminate than protein within the insoluble fraction. A theoretical yield of 
979mg purified protein was determined to be obtainable from a 20L fermentation run, using the opti-
mized purification scheme (insoluble procedure using 1M Gdn-HCl as the denaturant). This corresponds 
to nearly 500,000 doses per run, assuming the effective dose is 5μg. Endotoxin contamination was re-
duced to 1.85EU/μg, which is within the acceptable range of exposure for a vaccine. 
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Figure 3.6 Western Blot of FliC samples, insoluble and soluble fractions 
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Figure 3.7 Anion Exchange Chromatogram FliC.  
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Table 3.1 Endotoxin levels detected using LAL assay, FliC 
Insoluble w/ 1M Gdn-HCl as denaturant
Sample EU/mL [protein] µg/mL
1M Gdn RL (ins) 3.64E+07 1183
AEX Peak 1 7.26E+02 392
Insoluble w/ 6M Gdn-HCl as denaturant
Sample EU/mL [protein] µg/mL
6M Gdn RL (ins) 2.63E+07 1166
AEX Peak 1 3.96E+02 None detected
AEX Peak 2 7.40E+01 None detected
Soluble w/ 6M Gdn-HCl as denaturant
Sample EU/mL [protein] µg/mL
6M Gdn RL (sol) 1.38E+07 1902
CAP 5.55E+05 892
AEX Peak 1 5.55E+04 13  
 
 
Figure 3.8 Endotoxin Levels during secondary purification, FliC 
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The purified protein must be properly refolded in order to stimulate TLR5. The TLR5 activity was 
quantified by measuring the optical density of samples which should increase as the activity increases. 
The percent activity was calculated by comparing the optical density of samples against the flagellin 
standard (Figure 3.9). Samples processed by both the insoluble and soluble procedures had high percent 
activity compared to the positive standard (86.75% and 91.41%, respectively). Additionally, protein puri-
fied by the insoluble procedure was positive for TLR5 activity in all preparations following protein refold-
ing, while only one of the peaks from AEX from the soluble procedure was positive for TLR5 activity. 
These results, together with the protein quantification results indicate that the insoluble procedure 
seemed to generate a higher level of properly folded flagellin. 
 
 
Figure 3.9 TLR5 Percent Activity, insoluble vs soluble (FliC) 
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Finally, the conditions for renaturation of solubilized protein were evaluated. There were no dis-
cernable differences in activity or quantity of protein based upon the time permitted for refolding (2 
hours or 24 hours, data not shown). However, altering the redox species did impart an effect on the abil-
ity to stimulate TLR-5. When the cysteine/cystine (cys/(cys)2) system was used, the percent activity was 
greater than the flagellin standard (111.74%). Changing the oxido-shuffle to glutathione (GSH-GSSG) re-
sulted in a reduction of activity (90.34%). The effect of the redox species used in refolding buffer may be 
minor, however when considering all the steps required for protein purification, even these slight differ-
ences may be impactful and worthy of consideration (Figure 3.10). 
 
 
Figure 3.10 TLR5 activity, varying redox species (FliC) 
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3.2 Results for STF2.HA1-2 (SI) 
Soluble and insoluble fractions of the second construct, STF2.HA1-2 (SI), were initially purified 
using varying concentrations of urea (1M, 2M, 4M, 6M) as the denaturing agent. By analysis of SDS-
PAGE and BCA assay data, use of a urea at high concentrations was found to deliver a high yield of pro-
tein (between 1337μg/ml and 8910μg/ml), but with residual contamination from host cell proteins (Fig-
ures 3.11, 3.12). The bands seen at around 37kDa represent contaminant, and the standard denoted “SI 
standard” (Lane 14) corresponds to the size of the target protein (76kDa). 
 
 
Figure 3.11 SDS PAGE 1 of Initial Purification of STF2.HA1-2(SI) from 20 Liter Fermentation Run.  
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Figure 3.12 SDS PAGE 2 of Initial Purification of STF2.HA1-2(SI) from 20 Liter Fermentation Run.  
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 Further experiments were performed in which varying concentrations (1M, 4M, 6M) of Guani-
dine Hydrochloride (Gdn-HCl) were used as the denaturant. The SDS-PAGE and BCA data from these 
preparations indicated that the protein yield when using Gdn-HCl as a denaturant was higher than the 
yield associated with urea in both insoluble and soluble fractions (3924μg/ml – 16914μg/ml), regardless 
of the concentration used (Figures 3.13, 14). Again, the relationship between denaturant concentration 
and protein yield appears to be directly proportional but using Gdn-HCl even at low concentration still 
returned a relatively high concentration of target protein with less residual contamination. Using Gdn-
HCl as a denaturant appeared to resolve many of the contaminating host protein issues that were seen 
in preparations using urea. 
 
Figure 3.13 SDS PAGE 3 of Initial Purification of STF2.HA1-2(SI) from 20 Liter Fermentation Run.  
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Figure 3.14 SDS PAGE 4 of Initial Purification of STF2.HA1-2(SI) from 20 Liter Fermentation Run.  
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 Following initial purification of the insoluble fraction, refined lysate generated using Gdn-HCl as 
a denaturant was further clarified by AEX chromatography (Figure 3.15). The purpose of AEX was to re-
duce contamination by endotoxin. All concentrations of Gdn-HCl resulted in greatly reduced ET (Figure 
3.16), but a higher concentration of Gdn-HCl (6M) resulted in better removal of endotoxin from prepara-
tions. Additionally, the protein yield was far greater (1302μg/mL) when using a high concentration of 
denaturant. These results indicate that using a 6M concentration of Gdn-HCl as the denaturant is best 
suited for the purification of this construct and further demonstrate the value of harvesting the protein 
within the insoluble fraction. This process generates a theoretical yield of purified protein from a 20L 
fermentation run is 3.2g, corresponding to approximately 650,000 doses. An effective dose was as-
sumed to be 5μg, however, significantly lower doses have been shown to be effective for this fusion pro-
tein (20). The residual endotoxin contamination is minimal: 1.5EU per dose. 
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Figure 3.15 SDS-PAGE of AEX Fractions (SI) 
 
 
 
 
Figure 3.16 Endotoxin Levels during Secondary Purification (SI) 
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3.3 Results for FliC:GP132 
Early sampling during fermentation indicated that a large quantity of the fusion protein desig-
nated FliC:GP132 was found in the spent media (Figure 3.16). Thus, initial experimentation focused on 
an approach designed to maximize potentially secreted target protein. Spent media was collected cen-
trifuged to initially clarify desired protein from cell contaminants. The resulting insoluble and soluble 
fractions were processed further. The insoluble pellet was rinsed and then resuspended in resolublizing 
buffer using varying concentrations of Gdn-HCl (1M, 6M). PEG was added to the soluble fraction (super-
natant) to precipitate the target protein. A second centrifugation step was performed to collect precipi-
tated protein. The pellet was recovered, rinsed, and resuspended in buffer containing either 1M or 6M 
Gdn-HCl. The yield of protein was very low for this procedure: below 400µg/mL for all conditions. Thus, 
no further processing of these samples was attempted.  
Cell paste was processed by both the insoluble and the soluble procedure, using either 1M or 
6M Gdn-HCl as the denaturant. Purification of the previous constructs (full-length flagellin and the SI fu-
sion protein) indicated that Gdn-HCl was a more efficacious denaturant than urea. Process samples were 
analyzed by SDS-PAGE to detect presence of target protein (~50kDa) and by BCA protein assay to quan-
tify protein. Samples processed by the insoluble procedure resulted in low protein yield (590-
12634µg/mL); additionally, host cell contaminants were present. Thus, only samples from the soluble 
procedure were processed further. Yields following preliminary processing using the soluble procedure 
ranged from 6016µg/mL when using 6M Gdn-HCL to 10664µg/mL when using 1M Gdn-HCl. These initial 
results indicate that this construct is optimally processed using the soluble fraction at a low concentra-
tion of Gdn-HCl (1M) (Figure 3.17).  
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Figure 3.17 SDS PAGE 1 of Initial Purification of FliC:GP132 from 20 Liter Fermentation Run.  
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Following initial purification, buffer exchange was performed using tangential flow filtration 
(TFF), followed by a 2-phase spin and filtration in order to reduce contaminating GNB components. Total 
protein yield for samples after secondary processing (called “post-TFF refined lysate”) was 3377µg/mL 
(Figure 3.18). The post-TFF refined lysate was then refolded for either 2 or 24 hours using varying redox 
species in preparation for column loading and final clarification by anion exchange chromatography.  
The chromatogram generated by AEX showed a peak at ~15% gradient, indicating the target 
protein was eluted (Figure 3.19). Protein concentration of the first peak was quantified using a BCA pro-
tein assay (3238µg/mL). SDS-PAGE analysis also indicated the presence of target protein (Figure 3.20). 
Significant protein loss occurred during column-binding (4019μg/mL), which could be a result of over-
loading protein onto the column, or poor binding of the protein due to the presence contaminants. 
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Figure 3.18 SDS PAGE 2 of TFF and 2 Phase Separation of FliC:GP132 from 20 Liter Fermentation Run.  
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Figure 3.19 Anion Exchange Chromatogram FliC:GP132.  
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Figure 3.20 SDS-PAGE of AEX Peaks (FliC:GP132) 
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Samples processed through AEX were validated using Western Blotting (Figure 3.21). Hybridiza-
tion of the purified protein to the antibody indicated that the epitope portion of the fusion protein was 
present and detectable. Endotoxin levels were quantified following each stage of purification. The con-
centration of ET decreased after each process step, with the largest decrease in contamination occurred 
following 2-phase separation (Figure 3.22). Endotoxin levels were reduced from 109EU/mL in the refined 
lysate to 104EU/mL following AEX.  
 
Figure 3.21 Western Blot of purified FliC:GP132 samples from 30 Liter Fermentation Run.  
 
 
Figure 3.22 Endotoxin Levels during Secondary Purification (FliC:GP132) 
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Finally, biological activity of purified FliC:GP132 was measured using a TLR-5 assay. The refolding 
efficiencies of different redox species used in the refolding buffer was compared. Refolded protein was 
highly active (101.65% activity – 131.67% activity) compared to the flagellin standard. Refolding protein 
in the presence of the glutathione redox system appeared to yield more active than protein refolded us-
ing the cysteine system (Figure 3.23). 
 
Figure 3.23 TLR-5 Activity, varying redox species (FliC:GP132) 
 
Endotoxin contamination was 18EU/μg, which indicates that this preparation does not meet the 
criteria for pharmaceutical-grade protein. Processing the soluble fraction was more effective for this 
construct. Further, a low concentration (1M) of Gdn-HCl was considered to be optimal. If processed un-
der the recommended conditions, the theoretical yield for FliC:GP132 is 8.1g protein per 20L fermenta-
tion run. Thus, there is a potential for obtaining 1.6 million doses of vaccine from a single 20L fermenta-
tion run (assuming a 5μg dose).  
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4.  CONCLUSIONS 
In this study, a multistep approach was taken to optimally purify recombinant proteins produced in an E. 
coli expression system: full-length flagellin, flagellin fused to an antigenic portion of influenza, and fla-
gellin fused to an antigenic region of Marburgvirus. Purification schemes which recovered target protein 
from both the insoluble and soluble fractions were compared, as approaches which only focus on one 
fraction fail to capture valuable protein produced in the opposite fraction. It is unclear what characteris-
tic about the constructs causes the difference in the expression in the insoluble or soluble fraction, as 
well as whether the protein can be best purified from the insoluble or soluble fraction. There is still no 
universal procedure for purification of proteins from GNB, and purification systems need to be devel-
oped which maximize retrieval of proteins from both insoluble and soluble fractions. The ideal purifica-
tion structure should yield target protein produced in high quantity, be easily purifiable, and have simi-
lar activity to protein in native conformation. These targets were met for each of the constructs exam-
ined, though the methodology used varied. For full-length flagellin (FliC) and the flagellin-influenza fu-
sion protein (STF2:HA1-2(SI)), processing protein from the insoluble fraction was shown to result in high 
yields: up to 1-3g of protein per 20L fermentation run. For the flagellin-Marburgvirus fusion protein 
(FliC:GP132), greater yield was obtained by processing the soluble fraction (up to 8g protein per 20L fer-
mentation run). 
The approach taken in this study was intended to create a blueprint for protein purification from 
GNB. Variables which were examined included the type of denaturant used, under which conditions pro-
tein was best resolubilized, as well as comparing the quantity and quality of protein from the insoluble 
and soluble fractions. It was hypothesized that purification in the insoluble fraction may reduce the 
number of purification steps required for highly active protein. A second hypothesis posited that altering 
the type and concentration of denaturant could reduce loss of target protein due to misfolding or the 
formation of aggregates. TLR5 activity for the FliC construct purified from the insoluble fraction was 
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comparable to the flagellin standard. Additionally, endotoxin levels were greatly reduced in samples 
processed by the insoluble procedure, compared to the endotoxin contamination in samples from the 
soluble fraction. Endotoxin contamination for the SI construct purified from the insoluble fraction using 
Gdn-HCl was similar to previously reported levels using urea as a denaturant and purifying solely from 
soluble fraction (data confidentially reported). Bioactivity of FliC:GP132 was like flagellin standard ac-
cording to TLR5 assays, though endotoxin was levels were higher than desirable.  
The use of Gdn-HCl as a denaturant was effective for all the constructs purified. It has been widely 
shown that Gdn-HCl can be used effectively to purify proteins from Gram negatives, but usually at 
higher concentrations than appeared necessary for the preparations SI, FliC, and FliC:GP132. Using a 
lower concentration of denaturant during the initial stages of the purification process is advantageous in 
that there should be fewer downstream steps required to remove it from the preparation. The concern 
with purification of proteins from the insoluble fraction has always been than protein will be misfolded 
or aggregated and not functional. These data show that active, properly folded protein was able to be 
obtained from the insoluble fraction using lower concentration of denaturant than has been previously 
demonstrated.  
In order to take full advantage of the speed and low-cost nature of bacterial protein expression sys-
tems, more focus has been put on methods that extract protein produced within inclusion bodies. It was 
hypothesized that production of target protein within inclusion bodies could be exploited because of the 
lack of host cell contaminants within inclusion bodies as well as the tendency of E. coli to express a high 
concentration of recombinant protein therein. Use of this method yields active product at the high con-
centration with little endotoxin contamination. It appears that that is the case for certain proteins, but 
not for all. For instance, this approach was not suitable for the purification of the construct containing 
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Marburg virus, FliC:GP132. In the future, use of computational models to predict the solubility of con-
structs may be useful in predicting whether target protein is produced within the soluble or insoluble 
fraction. 
Purification of proteins from inclusion bodies requires some distinct considerations. The most cru-
cial step is refolding of solubilized protein, as misfolding often occurs within inclusion bodies. Refolding 
methods vary based on the technique used to refold protein, the type chemical that aids in refolding, 
whether there are chaperone molecules present, and length of the process. Guanidine-HCl acts as a cha-
otrophic agent: using a low concentration of this denaturant to resolubilize protein from IBs can main-
tain or recover native structure of target proteins, while urea has been shown to sometimes increase 
the likelihood of secondary structures or aggregates forming. The time allowed for refolding (2 hours or 
overnight) did not influence the quality of protein, which was expected. Rapid dilution was utilized to 
refold protein and allowing the protein to stir once refolded for a longer period of time should not have 
an effect on the activity of protein. The redox system used in refolding buffer (either oxidized and re-
duced cysteine or glutathione) were evaluated for effectiveness based on TLR5 activity: both systems 
were efficient for all constructs tested, though there were variations seen among different constructs.  
For FliC, higher activity was observed when using the cysteine/cystine (cys/(cys)2) redox system within 
the refolding buffer. Conversely, refolding FliC:GP132 in the presence of the glutathione redox system 
appeared to yield more active than protein refolded using the cysteine system. The effect of the redox 
species used in refolding buffer may be minor, however when considering the totality of variables in-
volved in creating an ideal protein purification scheme, slight variances such as these cannot be ignored. 
 Anion exchange chromatography was used as the final purification step in all purification proce-
dures studied. A significant amount of protein was lost to column flow-through; this was especially true 
for the FliC:GP132 fusion protein. This result, combined with the high level of residual endotoxin con-
tamination indicate that it is likely that endotoxin contamination prevented proper binding of protein to 
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the column during the final chromatography step. This is an issue that may have been reduced by re-
moving excess ET in prior stages of purification. Repeating the 2 – phase spin or introducing this step 
earlier in the process may reduce ET prior to loading on the column. Adding this step does not greatly 
affect the amount of time or resources needed for protein purification, nor does it introduce any addi-
tives that would have to be removed by adding an additional step later in purification. AEX chromatog-
raphy is a purification step ideally placed near the end of the purification scheme because the product 
eluted from the column should have very minimal contaminants and therefore will require few, if any, 
downstream steps. 
 Purification of proteins from Gram negative bacteria can be challenging, and unfortunately, 
there is still no one universal method to be used to achieve this goal. The iterative nature of the purifica-
tion process may be reduced or optimized by performing a meta-analysis of the literature of proteins 
purified from E. coli, in order to build a database of protein characteristics and successful purification 
schemes. This, combined with in silico protein folding and characterization, may provide insight into 
which purification system is the most appropriate for the putative protein. This may be especially useful 
when the putative protein is truncated or a fusion protein. The expression and characteristics of such 
proteins may be difficult to predict, thus in silico modeling would greatly reduce troubleshooting. More-
over, it may be more advantageous to produce recombinant protein in newer cell-free systems, recom-
binant E. coli which does not express LPS at all (45), or within a eukaryotic or Gram-positive bacterial ex-
pression system. At any rate, a blueprint of all possible protein purification methodologies is a useful 
tool regarding expediting the process of purification and reduction of unpredictable variables. This study 
integrates valuable information into such a blueprint by demonstrating that a less stringent denaturant 
may be used to effectively purify biologically active recombinant protein from the insoluble fraction of 
an E. coli expression system.   
66 
 
REFERENCES 
1.  Villaverde A, Carrió MM. 2003. Protein aggregation in recombinant bacteria: Biological role of in-
clusion bodies. Biotechnol Lett 25:1385–1395. 
2.  Rietschel E, Kirikae T, Schade FU, Mamat U, Schmidt G, Loppnow H, Ulmer A, Zahringer U, Seydel 
U, Di Padiva F, Schreier M, Brade H. 1994. Bacterial endotoxin: molecular relationships of sturcture 
to activity and function. FASEB J 8:217–225. 
3.  FDA. 2015. Inspection Technical Guide: Bacterial Endotoxins/Pyrogens. US FDA. 
4.  Heumann D, Roger T. 2002. Initial responses to endotoxins and Gram-negative bacteria. Clin Chim 
Acta 323:59–72. 
5.  Su W, Ding X. 2015. Methods of Endotoxin Detection. J Lab Autom 20:354–364. 
6.  Hirayama C, Sakata M. 2002. Chromatographic removal of endotoxin from protein solutions by 
polymer particles. J Chromatogr B Analyt Technol Biomed Life Sci 781:419–432. 
7.  Wang X, Quinn PJ. 2010. Lipopolysaccharide: Biosynthetic pathway and structure modification. 
Prog Lipid Res 49:97–107. 
8.  Gnauck A, Lentle RG, Kruger MC. 2016. Chasing a ghost?-Issues with the determination of circulat-
ing levels of endotoxin in human blood. Crit Rev Clin Lab Sci 53:197–215. 
9.  Chen RH, Huang CJ, Newton BS, Ritter G, Old LJ, Batt CA. 2009. Factors affecting endotoxin removal 
from recombinant therapeutic proteins by anion exchange chromatography. Protein Expr Purif 
64:76–81. 
67 
 
10.  Marcelino J, Lima JLFC, Reis S, Matos C. 2007. Assessing the effects of surfactants on the physical 
properties of liposome membranes. Chem Phys Lipids 146:94–103. 
11.  Liu S, Tobias R, McClure S, Styba G, Shi Q, Jackowski G. 1997. Removal of Endotoxin from Recombi-
nant Protein Preparations. Clin Biochem 30:455–463. 
12.  Anspach FB, Hilbeck O. 1995. Removal of endotoxins by affinity sorbents. J Chromatogr A 711:81–
92. 
13.  Clark ED. 2001. Protein refolding for industrial processes. Curr Opin Biotechnol 12:202–7. 
14.  Carrió MM, Cubarsi R, Villaverde A. 2000. Fine architecture of bacterial inclusion bodies. FEBS Lett 
471:7–11. 
15.  Singh A, Upadhyay V, Upadhyay AK, Singh SM, Panda AK. 2015. Protein recovery from inclusion 
bodies of Escherichia coli using mild solubilization process. Microb Cell Factories 14:41. 
16.  Peternel Š, Grdadolnik J, Gaberc-Porekar V, Komel R. 2008. Engineering inclusion bodies for non 
denaturing extraction of functional proteins. Microb Cell Factories 7:34. 
17.  Palmer I, Wingfield PT. 2004. Preparation and Extraction of Insoluble (Inclusion-Body) Proteins 
from Escherichia coli. Curr Protoc Protein Sci Editor Board John E Coligan Al CHAPTER:Unit-6.3. 
18.  Janeway CA, Medzhitov R. 2002. Innate Immune Recognition. Annu Rev Immunol 20:197–216. 
19.  Medzhitov R, Janeway Jr CA. 1997. Innate immunity: impact on the adaptive immune response. 
Curr Opin Immunol 9:4–9. 
20.  Song L, Nakaar V, Kavita U, Price A, Huleatt J, Tang J, Jacobs A, Liu G, Huang Y, Desai P, Maksymiuk 
G, Takahashi V, Umlauf S, Reiserova L, Bell R, Li H, Zhang Y, McDonald WF, Powell TJ, Tussey L. 
68 
 
2008. Efficacious recombinant influenza vaccines produced by high yield bacterial expression: A 
solution to global pandemic and seasonal needs. PLoS ONE 3. 
21.  Huleatt JW, Jacobs AR, Tang J, Desai P, Kopp EB, Huang Y, Song L, Nakaar V, Powell TJ. 2007. Vac-
cination with recombinant fusion proteins incorporating Toll-like receptor ligands induces rapid 
cellular and humoral immunity. Vaccine 25:763–775. 
22.  McSorley SJ, Ehst BD, Yu Y, Gewirtz AT. 2002. Bacterial flagellin is an effective adjuvant for CD4+ T 
cells in vivo. J Immunol Baltim Md 1950 169:3914–9. 
23.  Liu F, Yang J, Zhang Y, Zhou D, Chen Y, Gai W, Shi W, Li Q, Tien P, Yan H. 2010. Recombinant flagel-
lins with partial deletions of the hypervariable domain lose antigenicity but not mucosal adjuvancy. 
Biochem Biophys Res Commun 392:582–587. 
24.  Lu Y, Swartz JR. 2016. Functional properties of flagellin as a stimulator of innate immunity. Sci Rep 
6:1–11. 
25.  Thompson WW, Comanor L, Shay DK. 2006. Epidemiology of Seasonal Influenza: Use of Surveil-
lance Data and Statistical Models to Estimate the Burden of Disease. J Infect Dis 194:S82–S91. 
26.  Flannery B, Chung JR, Belongia EA, McLean HQ, Gaglani M, Murthy K, Zimmerman RK, Nowalk MP, 
Jackson ML, Jackson LA, Monto AS, Martin ET, Foust A, Sessions W, Berman LS, Barnes JR, Spencer 
S, Fry AM. 2018. Interim estimates of 2017–18 seasonal influenza vaccine effectiveness — United 
States, February 2018. MMWR 18:1020–1025. 
27.  Misawa S, Kumagai I. 1999. Refolding of Therapeutic Proteins Produced in Escherichia coli as Inclu-
sion Bodies. Biopolym Pept Sci 51:297–307. 
69 
 
28.  Friede M, Palkonyay L, Alfonso C, Pervikov Y, Torelli G, Wood D, Kieny MP. 2011. WHO initiative to 
increase global and equitable access to influenza vaccine in the event of a pandemic: Supporting 
developing country production capacity through technology transfer. Vaccine 29:A2–A7. 
29.  Brauburger K, Hume AJ, Mühlberger E, Olejnik J. 2012. Forty-five years of marburg virus research. 
Viruses 4:1878–1927. 
30.  Leffel EK, Reed DS. 2004. Marburg and Ebola viruses as aerosol threats. BiosecurBioterror 2:186–
191. 
31.  Middelberg APJ. 2002. Preparative protein refolding. Trends Biotechnol 20:437–443. 
32.  Singh SM, Panda AK. 2005. Solubilization and refolding of bacterial inclusion body proteins. J Biosci 
Bioeng 99:303–310. 
33.  Futami J, Tsushima Y, Tada H, Seno M, Yamada H. 2000. Convenient and efficient in vitro folding of 
disulfide-containing globular protein from crude bacterial inclusion bodies. J Biochem (Tokyo) 
127:435–441. 
34.  Upadhyay AK, Singh A, Mukherjee KJ, Panda AK. 2014. Refolding and purification of recombinant L-
asparaginase from inclusion bodies of E. coli into active tetrameric protein. Front Microbiol 5:1–10. 
35.  Lim WK, Rosgen J, Englander SW. 2009. Urea, but not guanidinium, destabilizes proteins by form-
ing hydrogen bonds to the peptide group. Proc Natl Acad Sci 106:2595–2600. 
36.  De Bernardez Clark E. 1998. Refolding of recombinant proteins. Curr Opin Biotechnol 9:157–163. 
37.  Kalina W V., Warfield KL, Olinger GG, Bavari S. 2009. Discovery of common marburgvirus protec-
tive epitopes in a BALB/c mouse model. Virol J 6. 
70 
 
38.  Jobe A, Sadler JE, Bourgeois S. 1974. lac Repressor-operator interaction. J Mol Biol 85:231–248. 
39.  Pizarro SA, Gunson J, Field MJ, Dinges R, Khoo S, Dalal M, Lee M, Kaleas KA, Moiseff K, Garnick S, 
Reilly DE, Laird MW, Schmelzer CH. 2010. High-yield expression of human vascular endothelial 
growth factor VEGF165in Escherichia coli and purification for therapeutic applications. Protein 
Expr Purif 72:184–193. 
40.  Yang XA, Dong XY, Li Y, Wang YD, Chen WF. 2004. Purification and refolding of a novel cancer/tes-
tis antigen BJ-HCC-2 expressed in the inclusion bodies of Escherichia coli. Protein Expr Purif 
33:332–338. 
41.  Aida Y, Pabst MJ. 1990. Removal of endotoxin from protein solutions by phase separation using 
triton X-114. J Immunol Methods 132:191–195. 
42.  Tsumoto K, Ejima D, Kumagai I, Arakawa T. 2003. Practical considerations in refolding proteins 
from inclusion bodies. Protein Expr Purif 28:1–8. 
43.  Roskov A, Larsson B, Gillstrom S, Bjornestedt R, Schmidt S. 2007. Large-Scale Production of Endo-
toxin-Free Plasmids for Transient Expression in Mammalian Cell Culture. Biotechnol Bioeng 
99:557–566. 
44.  Patel A V., Trambadiya DA, Baldaniya L. 2013. Water quality for Pharmaceutical use : A review. 
Pharma Sci Monit 4:29–63. 
45.  Schwarz H, Gornicec J, Neuper T, Parigiani MA, Wallner M, Duschl A, Horejs-Hoeck J. 2017. Biologi-
cal Activity of Masked Endotoxin. Sci Rep 7. 
 
  
71 
 
APPENDICES  
Appendix A- Insoluble Procedure for Initial Purification of Recombinant Proteins 
Procedure: 
Preparing the Cell Extract 
1. Thawing Cell Extract 
a. Record bioreactor batch information, construct ID, and amount (weight and quantity) of cell 
extract to thaw 
b. Remove frozen cell extract from storage (record storage temperature) 
c. Place frozen cell extract in 4ºC to thaw overnight 
2. Addition of Lysis Buffer 
a. Retrieve cell extract and Lysis Buffer (P1) from refrigerator  
b. Add a small amount of Lysis Buffer to volumetric container with the capacity to hold 1.5L 
c. Begin stirring Lysis Buffer with a stir bar 
d. Add cell extract to stirring Lysis Buffer 
e. Rinse cell extract bottle with Lysis Buffer 
f. Continue to add a total of 1L of Lysis Buffer to cell extract. 
g. Mix on stir plate for at least 15 minutes 
h. Place prepared cell extract in fridge to store or into ice bath to cool to <5ºC 
72 
 
Homogenization 
1. Prepare the Homogenizer 
a. Replace water in recirculating cooling loop with fresh ddH2O, place into ice bath 
b. Begin pumping (set flow to 50-100mL/min) 
c. Clean APV 
1. Fill hopper with 2L chilled ddH2O and run through 
2. Fill feed hopper with chilled lysis buffer and recirculate 3-5 minutes at 0psi (0bar) 
3. Discard lysis buffer 
2. Resuspend Cell Extract 
a. Record start temperature of the prepared cell extract 
b. Fill feed hopper with prepared cell extract 
c. Run sample through the APV at 0psi (0bar) 
d. Take sample of resuspended cell extract (“Resuspended Cell Extract”) 
e. Cool resuspended cell extract to <5ºC 
3. Homogenization 
a. Fill feed hopper with resuspended cell extract 
b. Run sample through the APV at 10,000psi (690bar) 
c. Cool lysate to <5ºC  
d. Repeat steps a-c until the lysate has been homogenized 3 times under pressure 
e. After the final pass, collect the lysate and cool to 14ºC 
f. Take a sample of the lysate (“Lysate”) 
g. Record final weight and volume of lysate 
h. If not processed immediately, store @ 4ºC 
73 
 
4. Clean the Homogenizer 
a. Fill feed hopper with ddH2O (1L) 
b. Run through and discard 
c. Fill feed hopper with fresh ddH2O (1L)  
d. Allow to recirculate at least 5min 
e. Drain hopper and discard 
f. Fill feed hopper with 0.1M NaOH 
g. Allow to recirculate 5-10min 
h. Drain hopper and discard 
Clarification by centrifugation 
1. Initial clarification 
a. Turn on centrifuge (Avanti J-20 XP) and set temp to 15ºC  
b. Aliquot equal volumes of the lysate into centrifuge bottles 
c. Load into centrifuge and spin for 45min @ 8,000rpm (decel to slow) 
d. After centrifugation, collect supernatant via pipetting, pool supernatants and measure total 
weight and volume 
e. Take sample of the pooled supernatant (“Pooled Supernatant”) 
f. Add Pellet Resuspension Buffer (P3, 1mL) to micro-centrifuge tube and add a loopful of pellet 
for sampling (“Initial Spin Pellet”) 
g. Discard the pellet 
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PEG Precipitation 
1. Addition of PEG 
a. Determine the amount of PEG-3350 required:  
 PEG= (pooled supernatant volume)*140g/L 
b. Weigh out required amount of PEG 
c. Slowly add the PEG to the pooled supernatant  
d. Mix on stir plate for at least 15 minutes 
2. PEG Precipitation Spin 
a. Turn on centrifuge (Avanti J-20 XP) and set temp to 15ºC  
b. Aliquot equal volumes of the prepared supernatant into centrifuge bottles 
c. Load into centrifuge and spin for 60min @ 10,000rpm (decel to zero) 
d. After centrifugation, decant and pool supernatants, measure total volume 
e. Take sample of pooled supernatant (“PEG Pooled Supernatant”) 
f. Discard supernatant 
Resuspension 
1. Resuspension of PEG pellet 
a. Add required volume of Resuspension Buffer (SOL1a or SOL1b) to pooled PEG pellets  
 Volume = volume of pooled supernatants from previous spin 
b. Disrupt mechanically using a disposable inoculation needle 
c. Mix with a stir bar until the pellet has been evenly resuspended 
d. Take sample of the resuspended pellet (“PEG Resuspension”) 
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2. Refined Lysate Spin 
a. Turn on centrifuge (Avanti J-20 XP) and set temp to 30ºC  
b. Aliquot equal volumes of the PEG resuspension into centrifuge bottles 
c. Load into centrifuge and spin for 60min @ 10,000rpm (decel to max) 
d. After centrifugation, collect and pool the supernatants 
e. Measure the total volume of the pooled supernatants, take sample (“Refined Lysate”) 
f. Label Refined Lysate with batch number and date; store at 4ºC 
g. Add Pellet Resuspension Buffer (P3, 1mL) to micro-centrifuge tube and add a loopful of pel-
let for sampling (“RL spin Pellet”) 
h. Discard the pellet 
Solutions: 
Lysis Buffer (P1) 
50mM Tris, 125mM NaCl, 4% Sucrose, 10mM EDTA, 0.05% TritonX-100, pH 8  
 Add 750ml ddH2O to a 1L beaker with a stir bar 
 Add 40g Sucrose 
 Stir until completely dissolved 
 Add 6.06g Tris 
 Add 7.3g Nicol 
 Add 3.72g EDTA 
 Add 0.5g TritonX-100 
 Stir for ~ 10 min 
 Adjust pH using Acetic Acid 
 Adjust volume to 1L with ddH2O 
 Filter sterilize, store at 4°C 
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Resuspension Buffer (SOL1a) 
200 mM Acetic Acid, 1M Guanidine-HCl, pH 4 
 Add 600ml ddH2O to a 1L beaker with a stir bar 
 Add 95.53g Guanidine-HCl  
 Stir until completely dissolved 
 Add 12mL of Glacial Acetic Acid 
 Stir for ~ 10 min 
 Adjust pH using NaOH. 
 Adjust volume to 1L with ddH2O 
 Filter sterilize, store at RT 
Resuspension Buffer (SOL1b) 
200 mM Acetic Acid, 6M Guanidine-HCl, pH 4 
 Add 600ml ddH2O to a 1L beaker with a stir bar 
 Add 573.18g Guanidine-HCl 
 Stir until completely dissolved 
 Add 12mL of Glacial Acetic Acid 
 Stir for ~ 10 min 
 Adjust pH using NaOH. 
 Adjust volume to 1L with ddH2O 
 Filter sterilize, store at RT 
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Pellet Resuspension Buffer (P3) 
100 mM Tris, 8 M Urea, pH 8  
 Add 500ml ddH2O to a 1L beaker with a stir bar 
 Add 480.48g Urea 
 Stir until completely dissolved 
 Add 12.112g Tris 
 Stir until completely dissolved 
 Adjust volume to 1L with ddH2O 
 Adjust pH using Acetic acid 
 Filter sterilize, store at RT 
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Appendix B- Soluble Procedure for Initial Purification of Recombinant Protein 
Preparing the Cell Extract 
1. Thawing Cell Extract 
a. Record bioreactor batch information, construct ID, and amount (weight and quantity) of cell 
extract to thaw 
b. Remove frozen cell extract from storage (record storage temperature) 
c. Place frozen cell extract in 4ºC to thaw overnight 
2. Addition of Lysis Buffer 
a. Retrieve cell extract and Lysis Buffer (P1) from refrigerator  
b. Add a small amount of Lysis Buffer to volumetric container with the capacity to hold 1.5L 
c. Begin stirring Lysis Buffer with a stir bar 
d. Add cell extract to stirring Lysis Buffer 
e. Rinse cell extract bottle with Lysis Buffer 
f. Continue to add a total of 1L of Lysis Buffer to cell extract. 
g. Mix on stir plate for at least 15 minutes 
h. Place prepared cell extract in fridge to store or into ice bath to cool to <5ºC 
Homogenization 
1. Prepare the Homogenizer 
a. Replace water in recirculating cooling loop with fresh ddH2O, place into ice bath 
b. Begin pumping (set flow to 50-100mL/min) 
c. Clean APV 
1. Fill hopper with 2L chilled ddH2O and run through 
2. Fill feed hopper with chilled lysis buffer and recirculate 3-5 minutes at 0psi (0bar) 
3. Discard lysis buffer 
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2. Resuspend Cell Extract 
a. Record start temperature of the prepared cell extract 
b. Fill feed hopper with prepared cell extract 
c. Run sample through the APV at 0psi (0bar) 
d. Take sample of resuspended cell extract (“Resuspended Cell Extract”) 
e. Cool resuspended cell extract to <5ºC 
3. Homogenization 
a. Fill feed hopper with resuspended cell extract 
b. Run sample through the APV at 10,000psi (690bar) 
c. Cool lysate to <5ºC  
d. Repeat steps a-c until the lysate has been homogenized 3 times under pressure 
e. After the final pass, collect the lysate and cool to 14ºC 
f. Take a sample of the lysate (“Lysate”) 
g. Record final weight and volume of lysate 
h. If not processed immediately, store @ 4ºC 
4. Clean the Homogenizer 
a. Fill feed hopper with ddH2O (1L) 
b. Run through and discard 
c. Fill feed hopper with fresh ddH2O (1L)  
d. Allow to recirculate at least 5min 
e. Drain hopper and discard 
f. Fill feed hopper with 0.1M NaOH 
g. Allow to recirculate 5-10min 
h. Drain hopper and discard 
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Clarification by centrifugation 
1. Initial clarification 
a. Turn on centrifuge (Avanti J-20 XP) and set temp to 15ºC  
b. Aliquot equal volumes of the lysate into centrifuge bottles 
c. Load into centrifuge and spin for 45min @ 8,000rpm (decel to slow) 
d. After centrifugation, collect supernatant via pipetting, pool supernatants and measure total 
weight and volume 
e. Take sample of the pooled supernatant (“Pooled Supernatant”) 
f. Add Pellet Resuspension Buffer (P3, 1mL) to micro-centrifuge tube and add a loopful of pel-
let for sampling (“Initial Spin Pellet”) 
g. Discard the pellet 
PEG Precipitation 
1. Addition of PEG 
a. Determine the amount of PEG-3350 required:  
 PEG= (pooled supernatant volume)*140g/L 
b. Weigh out required amount of PEG 
c. Slowly add the PEG to the pooled supernatant  
d. Mix on stir plate for at least 15 minutes 
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2. PEG Precipitation Spin 
a. Turn on centrifuge (Avanti J-20 XP) and set temp to 15ºC  
b. Aliquot equal volumes of the prepared supernatant into centrifuge bottles 
c. Load into centrifuge and spin for 60min @ 10,000rpm (decel to zero) 
d. After centrifugation, decant and pool supernatants, measure total volume 
e. Take sample of pooled supernatant (“PEG Pooled Supernatant”) 
f. Discard supernatant 
Resuspension 
1. Resuspension of PEG pellet 
a. Add required volume of Resuspension Buffer (SOL1a or SOL1b) to pooled PEG pellets  
 Volume = volume of pooled supernatants from previous spin 
b. Disrupt mechanically using a disposable inoculation needle 
c. Mix with a stir bar until the pellet has been evenly resuspended 
d. Take sample of the resuspended pellet (“PEG Resuspension”) 
2. Refined Lysate Spin 
a. Turn on centrifuge (Avanti J-20 XP) and set temp to 30ºC  
b. Aliquot equal volumes of the PEG resuspension into centrifuge bottles 
c. Load into centrifuge and spin for 60min @ 10,000rpm (decel to max) 
d. After centrifugation, collect and pool the supernatants 
e. Measure the total volume of the pooled supernatants, take sample (“Refined Lysate”) 
f. Label Refined Lysate with batch number and date; store at 4ºC 
g. Add Pellet Resuspension Buffer (P3, 1mL) to micro-centrifuge tube and add a loopful of pel-
let for sampling (“RL spin Pellet”) 
h. Discard the pellet 
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Solutions: 
Lysis Buffer (P1) 
50mM Tris, 125mM NaCl, 4% Sucrose, 10mM EDTA, 0.05% TritonX-100, pH 8  
 Add 750ml ddH2O to a 1L beaker with a stir bar 
 Add 40g Sucrose 
 Stir until completely dissolved 
 Add 6.06g Tris 
 Add 7.3g NaCl 
 Add 3.72g EDTA 
 Add 0.5g TritonX-100 
 Stir for ~ 10 min 
 Adjust pH using Acetic Acid 
 Adjust volume to 1L with ddH2O 
 Filter sterilize, store at 4°C 
Resuspension Buffer (SOL1a) 
200 mM Acetic Acid, 1M Guanidine-HCl, pH 4 
 Add 600ml ddH2O to a 1L beaker with a stir bar 
 Add 95.53g Guanidine-HCl  
 Stir until completely dissolved 
 Add 12mL of Glacial Acetic Acid 
 Stir for ~ 10 min 
 Adjust pH using NaOH. 
 Adjust volume to 1L with ddH2O 
 Filter sterilize, store at RT 
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Resuspension Buffer (SOL1b) 
200 mM Acetic Acid, 6M Guanidine-HCl, pH 4 
 Add 600ml ddH2O to a 1L beaker with a stir bar 
 Add 573.18g Guanidine-HCl 
 Stir until completely dissolved 
 Add 12mL of Glacial Acetic Acid 
 Stir for ~ 10 min 
 Adjust pH using NaOH. 
 Adjust volume to 1L with ddH2O 
 Filter sterilize, store at RT 
Pellet Resuspension Buffer (P3) 
100 mM Tris, 8 M Urea, pH 8  
 Add 500ml ddH2O to a 1L beaker with a stir bar 
 Add 480.48g Urea 
 Stir until completely dissolved 
 Add 12.112g Tris 
 Stir until completely dissolved 
 Adjust volume to 1L with ddH2O 
 Adjust pH using Acetic acid 
 Filter sterilize, store at RT 
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Appendix C- Tangential Flow Filtration and 2 Phase Separation 
Procedure:  
Preparing the TFF unit  
1. Pressure Hold Test  
a. Drain the system  
b. Tighten backpressure valve and clamp permeate line  
c. Introduce at least 5psi pressure to the system  
d. After 2 minutes, if the pressure has not dropped by 1psi, continue to next step. If the pressure 
has dropped, tighten both clamps and repeat until pressure is maintained.  
2. Retentate Flow Rate / Clean Water Flux  
a. Open backpressure valve and clamp permeate line  
b. Direct both permeate and retentate lines to waste.  
c. Direct feed line to reservoir of ddH2O  
d. Measure flow rate  
e. Direct retentate line to Feed Reservoir and unclamp permeate line  
f. Adjust backpressure to 5psi  
g. Establish permeate flow rate and calculate flux [(0.06*flow rate)/0.02]. Target flux is 200LMH  
h. Drain system  
3. Sanitize with Sanitization Buffer (P4)  
a. Make up fresh 0.1N NaOH (P4) for each use  
b. Open backpressure valve and direct feed and retentate lines to reservoir containing sanitiza-
tion buffer  
c. Once pH of permeate is at least 10, direct permeate line to sanitization buffer reservoir  
d. Recirculate 15 minutes, and drain the system  
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4. Rinse w/ ddH2O  
a. Direct retentate and permeate lines to waste  
b. Direct feed line to a reservoir containing ddH2O  
c. Flush 400mL through (as measured by the volume of the retentate)  
d. Clamp permeate line and measure pH of retentate  
e. Once pH of the retentate is 8 or less, open permeate line and tighten backpressure valve to 
give 5psi of pressure  
f. Measure pH of permeate  
g. Once the pH of the permeate is 8 or less, drain the system  
5. Equilibration  
a. Clamp permeate line and open backpressure valve  
b. Direct both feed and retentate lines to a reservoir containing diafiltration buffer (P2)  
c. Establish a consistent flow and unclamp the permeate line  
d. After 1 minute, check the pH of the permeate line. The pH of the permeate line should be at 
the same pH of the diafiltration buffer (+/- 0.5)  
e. Record pH and volume of permeate. Save 2x 1mL samples for endotoxin (ET) assay (“TFF EQ”).  
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TFF and 2-Phase  
1. Sample Prep and Concentration  
a. Retrieve refined lysate (RL) and record relevant sample information, including volume and ap-
pearance of sample  
b. Decant RL into fresh bottle, leaving behind white precipitate  
c. Record new volume (“original volume”) and pH of sample  
d. Add 1M Tris (P5) to bring pH of RL to 8, record volume of 1M Tris added  
e. Obtain 1x 1mL sample (“TFF start”)  
f. Measure conductivity of sample  
g. Direct feed and retentate lines to bottle containing sample  
h. Open permeate line and adjust backpressure valve to 5psi  
i. Concentrate RL to original volume (until volume in permeate reservoir is equivalent to volume 
of 1M Tris added)  
j. Take 1x 1mL samples of permeate, RL, and retentate (“Post Concentration RL”)  
87 
 
2. Buffer exchange  
a. Measure and record conductivity of diafiltration buffer  
b. Add diafiltration buffer feed line into sample reservoir  
c. Adjust backpressure valve to 5psi  
d. Begin running the system, adding diafiltration buffer to sample at the same rate as permeate 
outflow (maintain the original volume of RL)  
e. Once one diavolume (equivalent to the original volume of RL) has collected in the permeate 
reservoir, take 1mL samples of the retentate and permeate (“Diavolume 1”)  
f. Measure the conductivity of the permeate  
g. Repeat Steps d-f until 5 diavolumes have been run and the permeate conductivity is within 
10% of the conductivity of the diafiltration buffer  
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3. Filter Wash  
a. Drain TFF into retentate reservoir and record final volume  
b. Add 100 mL diafiltration buffer to clean container, direct feed and retentate lines to this con-
tainer  
c. Direct permeate line to waste  
d. Clamp the permeate line and recirculate for at least one minute to establish consistent flow  
e. Unclamp the permeate line and adjust backpressure to 5psi  
f. Continue to recirculate until volume remaining in feed reservoir is concentrated an amount 
equivalent to hold-up volume of the system (~30mL)  
g. Record final volume of the wash  
h. Pool wash and retentate from buffer exchange  
i. Record the weight and volume of the pooled retentates  
j. Take sample (“Post-TFF RL”)  
k. If the Post-TFF RL is not processed immediately, store @ 4ºC  
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4. 2-Phase Spin Procedure  
a. Add Triton X 114 (0.01 * weight of post-TFF RL)  
b. Stir for at least 15 minutes  
c. Add PEG 3350 (0.05 * weight of post-TFF RL)  
d. Stir until fully dissolved  
e. Aliquot prepared post-TFF RL into centrifuge bottles  
f. Begin 2-phase spin (10,000rpm at 24ºC for 3 hours, set decel to zero)  
g. Collect aqueous phase and detergent phase  
h. Take sample detergent phase (“Detergent Phase”), discard remainder  
i. Filter aqueous phase into clean container  
j. Weigh clarified aqueous phase and sample (“CAP”)  
k. Store CAP @ 4ºC 
Cleaning TFF unit  
1. Rinse with ddH2O  
a. Direct retentate and permeate lines to waste  
b. Open permeate clamp and adjust backpressure valve so that permeate flow and retentate 
flow are equal  
c. Direct feed line to reservoir containing 800mL ddH2O  
d. Flush all the water through the system  
e. Drain the TFF  
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2. Sanitize with 0.1N NaOH  
a. Open backpressure valve  
b. Direct feed and retentate lines to reservoir containing 0.1N NaOH  
c. Direct permeate line to waste  
d. Recirculate for about 1 minute  
e. Measure the pH of the permeate  
f. Once the permeate is at least 10, direct the permeate line to the feed reservoir  
g. Recirculate for 15 minutes  
h. Drain the TFF  
3. Rinse with ddH2O  
a. Direct retentate and permeate lines to waste  
b. Tighten backpressure valve so there is flow through the permeate line  
c. Flush 400mL ddH2O through the system  
d. Measure the pH of the permeate  
e. Once the pH of the permeate is 8 or less, open the backpressure valve and tighten the clamp 
on the permeate line  
f. Measure the pH of the retentate  
g. Once the pH of the retentate is 8 or less, drain the system  
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4. Store in 0.1N NaOH (P4)  
a. Open the backpressure valve  
b. Direct feed, retentate, and permeate lines to vessel containing 0.1N NaOH  
c. Start the pump  
d. Once the pH of the permeate is at least 10, stop the pump  
e. Clamp all tubing from the TFF unit to seal  
f. Store TFF unit at room temp  
Solutions:  
Diafiltration Buffer (P2)  
50mM Tris, 125mM NaCl, 10mM EDTA, pH 8  
 Add 750ml ddH2O to a 1L beaker with a stir bar.  
 Add 6.06g of Tris  
 Add 7.3g of NaCl  
 Add 3.72g of EDTA  
 Adjust pH using Acetic Acid  
 Adjust volume to 1L with ddH2O 
 Filter sterilize, Store at 4°C  
Sanitization Buffer (P4)  
0.1N NaOH  
 Add 990mL ddH2O to clean bottle  
 Add 10mL 10N NaOH, swirl to mix  
 Store @ RT  
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pH Adjustment Buffer (P5)  
1M TRIS  
 Dissolve 121.1g tris(hydroxymethyl)aminomethane in 1L ddH2O  
 Filter sterilize  
 Store @ RT  
93 
 
Appendix D- Phase 2 Purification 
Procedure: 
Preparation 
1. Add Guanidine-HCl to a 100mL aliquot of Refined Lysate (RL) sufficient to bring the concentra-
tion of Guanidine to 1M (9.53g). 
a. Mix on stir plate for at least 15 minutes 
2. Determine protein concentration of Denatured RL using BCA protein assay 
3. If required, dilute RL to 2mg/mL using Dilution Buffer (see Solutions); Final volume = at least 
25mL 
Refolding 
1. Record pH, conductivity, and batch information of Refolding Buffer (A1) 
2. Calculate volume of prepared RL containing at least 50mg protein (~25mL) 
3. Add required volume of Refolding Buffer  
a. Volume Refolding Buffer = 9*Volume of Diluted RL 
4. Slowly add Diluted RL (5mL/min) to Refolding Buffer and stir to refold for 2 hours 
5. Measure and record pH and conductivity of Refolded AEX Load 
6. Take sample (“Refolded AEX Load”) 
ÄKTA prep, Sample Load and Run 
1. Buffer prep set up for AEX 
a. Direct A11 inlet to 0.1M Tris solution 
b. Direct A2 inlet to 0.1M HCl 
c. Direct B1 inlet to sterile ddH2O 
d. Direct B2 inlet to 2M NaCl 
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2. Buffer line set up for additional methods (Clean/Strip/Store)  
a. Direct A16 inlet to A3 (Cleaning Solution) 
b. Direct A17 inlet to A2 (Stripping Solution)  
c. Direct A18 inlet to 20%EtOH 
3. Remove pH meter from storage solution and put in line 
4. Manually prime system pumps for ALL buffer lines 
a. Manual select Pump: Flow- 5mL/min (insert) 
b. Manual select Flowpath: Buffer Valve A1, position __ (insert) OR Pump A inlet, A2 (in-
sert) OR Pump B inlet, B1/B2 (insert) 
c. Execute commands 
d. Loosen corresponding valve port 
e. Connect syringe 
f. Draw all air from buffer line 
g. End command 
h. Repeat for each buffer line used 
5. Direct line from Refolded AEX Load (250mL sample to load) to sample valve (S1) 
6. Prime sample line 
a. Manual select Pump: Sample Flow_960- 5mL/min (insert) 
b. Manual select Flowpath: Sample Valve S1 (insert) 
c. Execute commands 
d. Watch for flow through with no bubbles. 
e. End command 
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7. Begin method queue “R3 Complete” on AKTA computer 
a. Method “Strip and Clean”  
i. Click “ok” on all options 
b. Method “Gradient Super Q 40411” 
i. Frac 950 collection- set to “row by row” 
ii. Evaluation Procedure- set to integrate full report  
iii. Click “ok” on all other options 
c. Method “Clean and Strip” 
i. Click “ok” on all options 
d. Method “EtOH for storage” 
i. Click “ok” on all options 
8. Collect post load wash, fractions, and load flow through, store at 4˚C. 
9. Replace pH meter into storage solution. 
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Solutions: 
Refolding Buffer (A1) 
20mM Tris, 0.1M Trehalose, 2mM CaCl2, 3mM Cysteine, 0.3mM Cystine, 1mM EDTA, 0.1% PS-80, pH 8.0 
 
 Add 1g of PS-80 into tared 1L beaker 
 Add 750ml ddH2O with a stir bar 
 Add 2.42g Tris 
 Add 34.23g Trehalose  
 Add 0.294g CaCl2 
 Add 0.527g Cysteine 
 Add 0.072g Cystine 
 Add 0.372g EDTA 
 Stir ~15min 
 Adjust pH with Glacial Acetic Acid 
 Adjust volume to 1L with ddH2O 
 Filter sterilize, Store at RT 
 Place 2-week expiration date on container 
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Stripping Buffer (A2) 
100mM Tris, 1M NaCl, pH 8 (Volume: 1L) 
 Add 750ml to a 1L beaker with a stir bar 
 Add 12.114g Tris 
 Add 58.44g NaCl 
 Stir ~10 min 
 Adjust pH using Acetic Acid 
 Adjust volume to 1L with ddH2O 
 Filter sterilize, store @ RT 
Q Cleaning Buffer (A3) 
0.5N NaOH, 1M NaCl 
 Add 750mL ddH2O to a beaker with a stir bar 
 Add 58.44g NaCl 
 Stir ~10min to mix thoroughly 
 Slowly add 20.0g NaOH pellets (exothermic reaction) 
 Stir ~10min to mix thoroughly 
 Adjust volume to 1L 
 Filter sterilize, store @ RT 
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Dilution Buffer (P3) 
100 mM Tris, 1M Guanidine-HCl, pH 8  
 Add 500ml ddH2O to a 1L beaker with a stir bar 
 Add 95.53g Guanidine-HCl 
 Stir until completely dissolved 
 Add 12.112g Tris 
 Stir until completely dissolved 
 Adjust pH using Acetic acid 
 Adjust volume to 1L with ddH2O 
 Filter sterilize, store at RT 
20% EtOH 
 Add 800mL ddH2O to sterile beaker 
 Add 200mL 100% EtOH (molecular grade) 
 Store at RT 
Buffer Prep 0.1M Tris (BP1) 
 Add 500mL ddH2O to a 1L beaker with a stir bar 
 Add 24.22g Tris 
 Stir until completely dissolved  
 Adjust volume to 2L with ddH2O 
 Filter sterilize, Store at RT 
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Buffer Prep 2M NaCl (BP2) 
 Add 500mL ddH2O to a 1L beaker with a stir bar 
 Add 233.8g NaCl 
 Stir until completely dissolved  
 Adjust volume to 2L with ddH2O 
 Filter sterilize, store at RT 
Buffer Prep 0.1M HCl (BP3) 
 Add 500mL ddH2O to a 1L beaker with a stir bar 
 Add 8.56g 36%HCl 
 Stir to mix 
 Adjust volume to 1L with ddH2O 
 Filter sterilize, store at RT 
Buffer Prep Sterile ddH2O (BP4) 
 Add 1L ddH2O to beaker 
 Autoclave liquid cycle at least 20 min 
 Store at RT 
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Method Queue Specifications: 
1. Column information:  
Anion Exchange 
ToyoScreen SuperA-650M 5mL prepacked column  
(Tosoh part number 21363) 
Maximum pressure:3bar (0.3MPa) 
Dimensions: 3cm H x 1.46cm D 
 
2. Buffer Prep: 
Species: Tris 
pH: 8 – range = 7.5-8.5 
 
3. Gradient:  
0-100% B (100% B= 1M NaCl) 
10 Column Volumes 
 
4. Clean and Strip/Strip and Clean: 
Clean with 3CV Stripping Solution (A2) 
Strip with 3CV Cleaning Solution (A3) 
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Appendix E- TLR5 Bioassay 
Procedure  
Ensure that both the HEK- Blue™-hTLR5 and HEK-Blue™-Null1 cells have been passaged with Test media 
at least once prior to performance of the assay (see HEK Cell Maintenance Procedure). 
HEK-Blue™-hTLR5 Cells 
Day 1: 
- Add 20 μl of each sample per well of a flat-bottom 96-well plate. 
- Add 20 μl of a positive control (flagellin from S. typhimurium, 100 ng/mL) in one well. 
- Add 20 μl of a negative control (sterile, endotoxin-free water) in one well. 
- Prepare a cell suspension of HEK-Blue™-hTLR5 Cells at ~140,000 cells per ml in Test Medium 
which contains 10% (v/v) heat inactivated FBS. 
- Add 180 μl of cell suspension (~25,000 cells) per well. 
- Incubate the plate at 37°C in a CO2 incubator for 20-24 h. 
Day 2: 
- Prepare QUANTI-Blue™ following the instructions on the pouch. 
- Add 180 μl of resuspended QUANTI-Blue™ per well of a flat-bottom 96-well plate. 
- Add 20 μl of induced HEK-Blue™-hTLR5 Cells supernatant. 
- Incubate the plate at 37°C incubator for 1-3 h. 
- Determine SEAP levels using a spectrophotometer at 620-655 nm. 
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HEK-Blue™-Null1 Cells 
Day 1: 
- Add 20 μl of each sample per well of a flat-bottom 96-well plate. 
- Add 20 μl of a positive control (TNFα, 100 ng/ml) in one well. 
- Add 20 μl of a negative control (sterile, endotoxin-free water) in one well. 
- Prepare a cell suspension of HEK-Blue™-Null1 Cells at ~280,000 cells per ml in Test Medium 
which contains 10% (v/v) heat inactivated FBS. 
- Add 180 μl of cell suspension (~50,000 cells) per well. 
- Incubate the plate at 37°C in a CO2 incubator for 16-20 h. 
 
Day 2: 
- Prepare QUANTI-Blue™ following the instructions on the pouch. 
- Add 180 μl of resuspended QUANTI-Blue™ per well of a flat-bottom 96-well plate. 
- Add 20 μl of induced HEK-Blue™-Null1 Cells supernatant. 
- Incubate the plate at 37°C incubator for 1-3 h. 
- Determine SEAP levels using a spectrophotometer at 620-655 nm. 
 
Once SEAP levels have been determined for both TLR5 and Null cells, subtract the Null ODs from the 
TLR5 ODs to correct for endogenous TLR5 activity in the HEK cells. The OD is directly proportional to the 
amount of TLR5 stimulation. 
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Appendix F- HEK Cell Maintenance 
HEK-Blue® hTLR5 and HEK-Blue® Null cell maintenance: 
Frozen cells (3rd passage) are stored in cryogenic vials in liquid N2 for long term storage. 
Growth medium (for both cell types): 
DMEM (500mL)—remove 58.5mL DMEM and discard 
add 50 mL FBS 
add 2.5 mL Pen/Strep 
add 5 mL glutamine 
add 1 mL Normocin 
Procedure: 
Add 5mL Growth media to T-25 flasks (1 per cell type).  
Label flasks with date, passage #, dilution (1:6), and cell type. 
Warm to 37˚C. 
Thaw cryovials and transfer 1mL cells to Growth media. 
After 4 days, or once confluency = 70-80%, transfer to Test media. 
Test medium (Null): 
 To 50mL Growth media, add 50µL Zeocin 
Test medium (hTLR5): 
 To 50mL Growth media, add 50µL Zeocin and 150µL Blasticidin. 
Procedure: 
Add 11.5mL Test media to T-75 flasks (2 per cell type).  
Label flasks with date, passage #, dilution (1:24), and cell type. 
Warm to 37˚C. 
Obtain cultures from incubator and check for 70-80% confluency. 
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Draw off spent media and wash twice with PBS. Draw off PBS and add fresh Test media (2mL). 
Pipet cells off flask, and tap gently to release. 
Add 500µL cell suspension to warmed new media, incubate @ 37˚C, 5%CO2. 
Transfer to fresh media every 4 days, or once confluency = 70-80%. 
** For frozen cells (after 20 passages, dispose of cell line and start from frozen cells). 
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Appendix G- Endotoxin Assay 
Procedure 
Pre-Assay Steps: 
All samples are tested for a pH of 8 using pH testing strips. Each sample is added to a pH strip until the 
tip of strip is wet, and then waits 30 seconds for color change. The strip is then compared to the test 
strip colors on the box to determine the pH of the sample. If samples are below 8 to 8.5, a buffer solu-
tion is added to increase the pH of the sample.  
LAL-free water is used for all dilutions, and all pipet tips and plates are pyrogen-free. All steps are done 
according to the manufacturer’s procedure. 
Preparation of the Standard: 
The standard is an E. coli endotoxin which is rehydrated with 2.3 mL of LAL-free water prior to use (via-
ble for one month). The concentration of this solution is 50 EU/mL. Diluent is LAL-free water. 
Standard should be vortexed before each use for 10 – 15 minutes. The standard should be at room tem-
perature for 15 minutes prior to use. Standard should be stored at 4° C.  
 
Standard Curve Dilutions: 
Dilution Standard Volume(µL) Diluent (µL) Total Volume(µL) 
1:5 50 450 500 
1:50 50 of 1:5 450 500 
1:500 50 of 1:50 450 500 
1:5000 50 of 1: 500 450 500 
 
Each dilution should be vortexed for ~ 1 minute between each serial dilution. Each sample should also 
be vortexed before it is added to microplate.  
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Sample Preparation:  
Pre-dilution:  
All samples from initial purification must be pre-diluted to 10-7. 
All samples from TFF/2Phase must be pre-diluted to 10-3. 
All samples from AEX need not be pre-diluted. 
Assay: 
Once samples have been pre-diluted (if necessary), prepare the dilutions for the assay as follows. 
 
Sample Dilutions: 
Dilution Sample Volume(µL) Diluent (µL) Total Volume(µL) 
1:5 80 320 400 
1:25 80 of 1:5 320 400 
1:125 80 of 1:25 320 400 
1:625 80 of 1:125 320 400 
 
Each dilution should be vortexed for ~ 1 minute between each serial dilution. Each sample should also 
be vortexed before it is added to microplate.  
Samples are incubated at 37°C for 5 minutes. 
The LAL reagent is then rehydrated with 2.6 mL LAL-free water and shaken until fully dissolved. LAL rea-
gent is then added to a reservoir. 
100µL of the LAL reagent is then added to every well with a sample by a multichannel pipette. The plate 
is then run for 40 minutes at 37°C using a pre-set protocol using the SoftMax Pro software on a Spectra-
Max Plus apparatus. It is important that no bubbles are present in the plate wells. 
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Parameters for SpectraMax Plus apparatus: 
Lonza Protocol 
 405 nm 
 Onset OD of 0.2 
 Interval of 2:30 min 
 Reads: 40 
 Constant Temperature of 37 degrees Celsius 
The data is then analyzed and calculated via SoftMax pro software.  
Standard Curve is generated with a log-log curve. A trend line is added to find the slope of the line and 
the R2 value. The equation is then used to calculate the x value. The x value for each sample is then mul-
tiplied by the dilution factors for each to obtain the amount of endotoxin for each sample.  
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Appendix H- BCA Protein Quantification 
Procedure 
(Adapted for Thermo Scientific Pierce BCA Protein Assay Kit) 
Prepare the working reagent- 1-part Reagent B : 50 parts Reagent A 
- Calculate the amount needed: 
- (# of samples x # of replicates x # of dilutions) + standards (in duplicate) 
Add 25µL of diluted standard to each well, in duplicate. 
Serial dilution of standards: 
2000µg (neat) 
1000µg (1:2 dilution of previous) 
500µg (1:2 dilution of previous) 
250µg (1:2 dilution of previous) 
125µg (1:2 dilution of previous) 
62.5µg (1:2 dilution of previous) 
31.25µg (1:2 dilution of previous) 
15.625µg (1:2 dilution of previous) 
0µg (ddH2O)  
Add 25µL of sample (diluted 1:10 and 1:20) to each well, in duplicate. 
Add 200µL working reagent to each well 
Incubate 30min @ 37°C (in the dark) 
Read Abs (562nm) using Spectrophotometer 
Generate chart plotting concentration of standards against absorbance. 
- Add trend line 
- Show R2 value and slope equation (y=mx+b) 
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Calculate protein concentration of samples: 
- Average replicate ODs 
- (Averaged value-b)/m 
- Multiply by dilution factor 
- Average dilutions of same samples 
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Appendix I- SDS-PAGE Assay 
Procedure: 
Preparing Samples  
1. Retrieve samples from -20°C 
2. Preparing non-reduced samples: 
a. Add sample, ddH2O, and 4x buffer to microcentrifuge tube according to the chart be-
low. 
b. Vortex each tube for ~10s to mix thoroughly. 
c. Briefly centrifuge samples. 
d. Heat on 95°C heating block for 5minutes. 
e. Allow to cool briefly. 
Sample ddH2O 4x sample 
buffer
Ratio μg 
Protein/10μL 
loaded
Initial 
Purification
4 26 10   1/10 1
TFF/2phase 12.5 17.5 10   1/2 5
Refold/ AEX 30 0 10   3/4 7.5
HIC 10 20 10   1/4 2.5
Bulk 
formulation
10 20 10   1/4 2.5
 
3. Preparing reduced samples (for CDC samples): 
a. Add sample (4µL), ddH2O (20µL), 10X Reducing Agent (6µL), and 4X Buffer (10µL). 
b. Vortex each tube for ~10s to mix thoroughly. 
c. Briefly centrifuge samples. 
d. Heat on 95°C heating block for 5minutes. 
e. Allow to cool briefly. 
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Loading Gel(s) 
1. Open pre-cast gel(s) and carefully remove tape and comb. 
2. Rinse gel(s) thoroughly with ddH2O. 
3. Insert gel(s) and spare plate, if necessary, into gel running apparatus. 
4. Lock securely into place. 
5. Add sufficient MOPS buffer (cool) to the upper and lower chambers. 
6. Add 4µL molecular weight marker to at least one well per gel using gel-loading tips. 
7. Add 10µL prepared sample to the well using gel-loading tips. 
Running Gel(s) 
1. Place the top of the gel-running apparatus onto the bottom chamber. 
2. Set the power supply to 200V, 1 hour. 
3. Start the run by pushing the “run” button. 
Viewing 
1. Fixing 
a. Once the run is finished, turn off the power supply and remove the gel(s). 
b. Prepare fixing solution. 
c. Carefully pry open gel cassette(s) using the gel knife. 
d. Place gel(s) into basket. 
e. Add required amount of fixing solution and allow gel(s) to shake for 10min @ RT. 
2. Staining 
a. Add prepared Coomassie Blue (10mL per gel) to gel(s) in fixing solution. 
b. Allow gel(s) to continue shaking for 3-16 hours. 
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3. De-staining 
a. Remove the staining solution by decanting. 
b. Add 200mL ddH2O. 
c. Shake the gel(s) for at least 3 hours or until stain is sufficiently reduced. 
4. Imaging 
a. Turn on light box of Gel Imager, 
b. Gently place gel on light box (one at a time), smooth out any bubbles, 
c. Manually adjust focus and aperture closure of the camera, 
d. Acquire image of the gel, 
e. Adjust exposure time and contrast as needed, 
f. Save modified image on a jump drive as both a jpg and a tif file. 
Solutions: 
Running Buffer  
 Add 950 mL of ddH2O to flask 
 Add 50 mL 20X NuPAGE MOPS SDS Running Buffer 
 Store @ 4ºC 
 Running buffer may be recycled up to 3 times 
Fixing Solution 
FIXING SOLUTION 1 GEL 2 GELS 3 GELS 4 GELS
Deionized Water (mL) 50 100 150 200
Methanol (mL) 30 60 90 120
Acetic Acid (mL) 10 20 30 40  
 
